WO2006119780A2

WO2006119780A2 - New antibiotic-sensitive lactic acid bacteria strains

Info

Publication number: WO2006119780A2
Application number: PCT/DK2006/050020
Authority: WO
Inventors: Per STRØMAN
Original assignee: Chr. Hansen A/S
Priority date: 2005-05-11
Filing date: 2006-05-11
Publication date: 2006-11-16
Also published as: EP2194125A3; EP1882034A2; US20120045820A1; RU2007145713A; US8021883B2; EP2194125A2; US20080171073A1; EP2264164A1; WO2006119780A3; BRPI0609093B1; RU2394911C2; BRPI0609093A8; US8440450B2; BRPI0609093A2

Abstract

Many probiotic Bifidobacteriacea contains an active tetW that renders the cells resistant to tetracycline. This may present a risk of a horizontal transfer of functional antibiotic genes. The present invention relates to a method of obtaining novel tetracycline-sensitive strains of the genus of Bifidobacteriacea {Bifidobacterium sp.). In particular, the present invention relates to novel antibiotic- sensitive strains obtained from antibiotic-resistant probiotic strains and the use of such novel strains for the preparation of a food or feed product or a dosage form comprising viable organisms.

Description

NEW ANTIBIOTIC-SENSITIVE LACTIC ACID BACTERIA STRAINS

FIELD OF THE INVENTION

The present invention pertains to a method of obtaining novel antibiotic-sensitive strains of the genus of Bifidobacterium from antibiotic-resistant Bifidobacteriacea carrying a chromosomal encoded antibiotic resistance gene and the strains obtainable by the method. In particular, the present invention relates to novel antibiotic-sensitive strains obtained from antibiotic-resistant probiotic strains and the use of such novel strains for the preparation of a food or feed product or a dosage form comprising viable organisms.

BACKGROUND OF THE INVENTION

Bacteria which ferment sugars with the production of acids in particular lactic acid as a major metabolic component have been known for a long time. Such bacteria may be found in milk or milk products, living or decaying plants but also in the intestine of hu- mans and animals. Traditionally, these bacteria have been referred to as "lactic acid bacteria". Lactic acid bacteria designate a rather heterologous group of Gram positive, non-motile, microaerophilic or anaerobic bacteria which ferment sugar with the production of acids including lactic acid and comprise e.g. the genera Bifidobacterium, Entero- coccus, Lactobacillus, Lactococcus, Leuconostoc and Pediococcus.

For centuries lactic acid bacteria have been used in the manufacture of food and feed products including most dairy products, and today lactic acid bacteria are essential in the making of all fermented milk products such as yoghurt, cheese and butter. Furthermore, lactic acid bacteria are widely used in the meat processing industry, wine manu- facturing industry, the juice manufacturing industry as well as a number of other industries.

Cultures of lactic acid bacteria also find important uses in the biopreservation of foodstuffs.

The publication of a large number of reports documenting that various lactic bacteria beneficially affect the well-being of humans and/or animals have attracted even further interest to this group of bacteria. In particular, specific strains of Lactobacillus or Bifidobacterium have been found to be able to colonize the intestinal mucosa and to assist in the maintenance of the well-being of the hosts. EP 0 768 375 describes specific strains of Bifidobacterium ssp, that are capable of being implanted in the intestinal flora and being capable to competitively exclude adhesion of pathogenic bacteria to intestinal cells. These Bifidobacteria are reported to assist in immunomodulation and thus in the maintenance of the individual's health. The immu- nomodulation effect of Bifidobacteria may even be conferred onto unborn children. WO 01/97822, e.g. describes that intake of Bifidobacterium animalis strain Bb-12® by the mother during her pregnancy reduces the occurrence of atopic diseases in children. Also WO 03/099037 describes that Bifidobacterium animalis strain Bb-12® are able to beneficially modify the immune response. According to Masco et al. (2004), Bifidobacte- rium animalis strain Bb-12® should correctly be referred to as Bifidobacterium animalis subsp. lactis strain Bb-12®.

Probiotic microorganisms have been defined as "Live microorganisms which when administered in adequate amounts confer a health benefit on the host" (FAO / WHO 2002). During the recent years, documentation on probiotic properties of Bifidobacteria and other lactic bacteria has accumulated. In general, the probiotic activity is associated with specific strains. The previously mentioned Bifidobacterium animalis strain Bb-12® as well as Bifidobacterium lactis strain HN019 have been reported as probiotic (WO 01/97822, WO 03/099037, Zhou et al. (2005), US 6379663).

Worldwide there is widespread public concern that the number of antibiotic resistant pa- togenic bacteria increases dramatically. All available data indicate that the disturbing increase in antibiotic resistant patogenic bacteria is caused by an extensive and very liberal use of antibiotics in the general population as well as in animal husbandry.

It is a well established fact that many antibiotic resistant bacteria carry genetic determinants, genes, which confer resistance to one or more antibiotics. It is furthermore wellknown that such genetic determinants under certain circumstances are transferable and may confer the antibiotic-resistant phenotype to recipient bacteria. The frequency of transfer is very much dependant on the particular genetic context in which the antibiotic resistance genes are found. I.e. antibiotic-resistant genes residing on plasmids or on transposons have been demonstrated to confer the antibiotic-resistant phenotype to recipient bacteria at relatively high frequencies, whereas chromosomally encoded determinants are very much less prone to move. For these reasons it may be of concern to ingest even beneficial, non-patogenic bacteria if they do contain an antibiotic resistant determinant. This concern is further emphasized in the report from the EUROPEΞAN COMMISSION'S Scientific Committee on Animal Nutrition (SCAN) on the Criteria for Assessing the Safety of Micro-Organisms Resistant to Antibiotics of Human Clinical and Veterinary of 3 July 2001 , revised on 24 January 2003, stating that the presence of a known resistance gene is not acceptable (page 21 ).

Resistance to tetracycline is the most common bacterial antibiotic resistance found in nature and similarly is the most widely distributed type of resistance among bacteria iso- lated from animals (Billington 2002). Tetracycline inhibits protein synthesis by binding to a single high-affinity site on the 3OS ribosomal subunit. With tetracycline in this position, the binding of aminoacyl-tRNA to the A site is prevented and thus protein synthesis is blocked.

Resistance to tetracycline may be mediated either by active efflux of tetracycline from the cell, by ribosomal protection by one or more soluble protein(s), the so-called ribosomal protection proteins (RPPs), or by enzymatic inactivation of tetracycline.

Recently, a new ribosome-protection-type tetracycline resistance (Tet^r) gene, tetW, was identified in rumen isolates of Butyrivibrio fibrisolvens and a number of other rumen bacteria (Barbosa, 1999).

Although the tetW determinant is widely distributed among tetracycline resistant isolates of animal patogens (Billington 2002), it was a surprise for the authors of this application to find that all known probiotic strains of Bifidobacterium animalis subs, lactis, including the two well-known Bifidobacterium strains Bb-12® and DR10™, carry a functional tetW determinant and are resistant to tetracycline; in particular because in a recent report the DR10™ strain as well as the Bb-12® strain were reported to be tetracycline sensitive (Zhou et al. 2005).

Even though extensive experiments have indicated that the tet W determinant of Bifidobacterium animalis subspecies lactis strain Bb-12® is not movable under realistic situations, the concern of antibiotic resistant determinants in food products still remains. Consequently, we have attempted several approaches to accomplish inactivation or re- moval of the tet W gene in Bifidobacterium animalis subspecies lactis Bb-12® by classi- cal mutagenesis, involving various mutagens, as well as by direct genetic manipulation. However, until now all attempts have been unsuccessful. It is contemplated that an important reason to the many unsuccessful attempts is the fact that the tetW is located on the chromosome of probiotic Bifidobacterium animalis subs, lactis strains.

Thus it would be highly advantageous to establish a method for the inactivation of the tetW resistance gene in probiotic Bifidobacteriacea. Such method could furthermore help to solve the problem of providing antibiotic sensitive variants of commercial interesting probiotic, tetracycline resistant Bifidobacteriacea, that may meet the requirement of absence of functional antibiotic resistance genes.

SUMMARY OF THE INVENTION

The above problem has been solved by providing a method of isolating a tetracycline- sensitive strain of Bifidobacterium sp. (Bifidobacteriacea) from a tetracycline-resistant bacterial progenitor strain wherein the antibiotic resistant phenotype is caused by the expression of a functional tetW that is stably integrated in its chromosome, said method comprising subjecting the cells both to a chemical mutagen and a physical mutagen. Preferably, the chemical mutagen comprises ethidium bromide (EtBr) and the physical mutagen is UV.

This method appears generally applicable to tetracycline resistant Bifidobacterium sp. with a functional tetW stably integrated in their chromosome, as in each of the mutagenizing experiments that we have conducted with this method were able to isolate tetracycline sensitive variants of the two Bifidobacterium strains Bb-12® and HN019 (DR10™).

Thus, further important aspects of the invention are the provision of strains of Bifidobacterium sp. containing a mutated, chromosomally encoded tetW rendering the strain sensitive to tetracyclines, which is obtainable by the above mentioned method, and the use of such Bifidobacterium strains for the preparation of an ingestible material or a medicament.

In a first aspect the present invention relates to a method of inactivating a tetW gene in a Bifidobacterium sp. (Bifidobacteriaceae) cell, said method comprising subjecting a Bi- fidobacterium sp. cell comprising a functional tetW gene to a chemical mutagen and a physical mutagen.

In a second aspect the present invention relates to a method of preparing a Bifidobacte- rium sp. cell comprising an inactivated fefWgene, said method comprising the steps of: a) inactivating a fefWgene in a Bifidobacterium sp. cell comprising a functional fefW gene by subjecting said cell to a chemical mutagen and a physical mutagen b) isolating a mutant of the Bifidobacterium sp. cell obtained from step a) which has an inactivated tetWgene.

In a third aspect the present invention relates to a method of preparing a tetracycline sensitive Bifidobacterium sp. cell, said method comprising the steps of: a) subjecting a Bifidobacterium sp. cell to a chemical mutagen and a physical mutagen, wherein the Bifidobacterium sp. cell has a Minimum Inhibitive Concentration of 4 mi- crogram tetracycline/ml or higher b) isolating a mutant of the Bifidobacterium sp. cell obtained from step a), wherein said mutant has a Minimum Inhibitive Concentration of 1.5 microgram tetracycline/ml or less.

In a fourth aspect the present invention relates to a Bifidobacterium sp. cell comprising an inactivated fefWgene.

In a fifth aspect the present invention relates a Bifidobacterium sp. cell which has a Minimum Inhibitive Concentration of 1.5 microgram tetracycline/ml or less.

In a sixth aspect the present invention relates to a Bifidobacterium sp. cell containing a mutated, chromosomally encoded tet W rendering the cell sensitive to tetracyclines obtainable by the method of the present invention.

In an seventh aspect the present invention relates to aBifidobacterium cell which is sensitive to tetracyclines due to a mutation in tetW, said Bifidobacterium cell being derived from a progenitor cell which is resistant to tetracyclines due to the presence of a tetW gene located on the chromosome. In an eight aspect the present invention relates to the use of a Bifidobacterium cell according to the present invention for the preparation of an ingestible material or a bacterial culture.

In a ninth aspect the present invention relates to a food or feed product comprising the bacterial cell of the present invention.

In a tenth aspect the present invention relates to a Bifidobacterium sp.cell according to present invention for the use as a probiotic.

In an elleventh aspect the present invention relates to a method of treating a mammal comprising administering a Bifidobacterium sp.cell according to present invention.

DETAILED DISCLOSURE OF THE INVENTION

In one embodiment the present invention relates to a method of inactivating a tetW gene in a Bifidobacterium sp. (Bifidobacteriaceae) cell, said method comprising subjecting a Bifidobacterium sp. cell comprising a functional tetW gene to a chemical mutagen and a physical mutagen.

The present invention further relates to a method of preparing a Bifidobacterium sp. cell comprising an inactivated tetW gene, said method comprising the steps of: a) inactivating a fefWgene in a Bifidobacterium sp. cell comprising a functional tetW gene by subjecting a Bifidobacterium sp. cell comprising a functional tetWgene to a chemical mutagen and a physical mutagen. b) isolating a mutant of the Bifidobacterium sp. cell obtained from step a) which has an inactivated fefWgene

In a further embodiment the present invention also relates to a method of preparing a tetracycline sensitive Bifidobacterium sp. cell, said method comprising the steps of: a) subjecting a Bifidobacterium sp. cell to a chemical mutagen and a physical mutagen, wherein the Bifidobacterium sp. cell has a Minimum Inhibitive Concentration of 4 microgram tetracycline/ml or higher b) isolating a mutant of the Bifidobacterium sp. cell obtained from step a), wherein said mutant has a Minimum Inhibitive Concentration of 1.5 microgram tetracycline/ml or less.

The reason why it has been difficult to mutate a fefWgene in a Bifidobacterium sp. cell may be that the gene is located on the chromosome of the cells. Thus, in a method of the present invention, the functional fefWgene may be located on the chromosome of the Bifidobacterium sp. cell.

Thus, in a method of the present invention the inactivated fefWgene may be located on the chromosome of the Bifidobacterium sp. cell.

The term "inactivated tetWgene" refers in the context of the present invention to a tetW gene which, if present in a cell, is not able to exert its normal function.

In particular an inactivated tetW gene is a gene which compared to a functional tetW gene comprises a mutation in the open reading frame (ORF) of the gene, wherein said mutation may be a frameshift mutation, introduction of a stop codon or a mutation which results in a non-conserved amino acid substition. Non-conserved amino acid substition is defined as a substitution of an amino acid residue for another amino acid residue with similar chemical properties (e.g. size, charge or polarity), which generally does not change the functional properties of the protein

In particular, an inactivated fefWgene is a fefWgene which, when present in a cell, makes said cell sensitive to tetracycline.

The term "functional fefWgene" refers in the context of the present invention to a tetW gene which, if present in a cell, makes the cell resistant to tetracycline. In particular a functional fefWgene may be a gene comprising an open reading frame (ORF) which has a sequence corresponding to position 1318-3234 in SEQ ID NO:22 or a sequence which has 30%, such as 40% or 50% or 60% or 70% or 80% or 85% or 90% or 95% or 99% homology to the sequence corresponding to position 1318-3234 of SEQ ID NO: 22.

For purposes of the present invention, alignments of sequences and calculation of homology scores may be done using a full Smith-Waterman alignment, useful for both protein and DNA alignments. The default scoring matrices BLOSUM50 and the identity matrix are used for protein and DNA alignments respectively. The penalty for the first resi- due in a gap is 12 for proteins and 16 for DNA, while the penalty for additional residues in a gap is 2 for proteins and 4 for DNA. Alignment may be made with the FASTA package version v20u6 (W. R. Pearson and D. J. Lipman (1988),"lmproved Tools for Biological Sequence Analysis", PNAS 85: 2444- 2448, and W. R. Pearson (1990) "Rapid and Sensitive Sequence Comparison with FASTP and FASTA", Methods in Enzymology, 183: 3'or N-terminal- > C-terminal direction of the nucleic acid or amino acid sequence, respectively.

It is a result of the present invention that the inventor is able to disclose a generally useful method for isolating a strain of Bifidobacterium sp. (Bifidobacteriacea) that contains a mutated tetWon its chromosome which renders the strain sensitive to tetracyclines and which is isolated from a tetracycline-resistant bacterial progenitor strain wherein the antibiotic resistant phenotype is caused by the expression of tet W stably integrated in its chromosome.

Reference to "progenitor strain" is in the present invention to be understood as reference to a Bifidobacterium sp. cell comprising a functional fefWgene, a tetracycline resistant Bifidobacterium sp. cell, or a Bifidobacterium sp. cell that has a MIC value of 4 microgram tetracycline/ml or higher. Reference to "antibiotic sensitive strain" is in the present invention to be understood as reference to a Bifidobacterium sp. cell comprising an inactivated fefWgene, a tetracycline sensitive Bifidobacterium sp. cell, or a Bifidobacterium sp. cell that has a MIC value of 1.5 microgram tetracycline/ml or less.

In one embodiment of the present invention, the Bifidobacterium cell may be a strain.

In a further embodiment the methods of the present invention may after step a) further comprises the steps of: i) transferring an aliquot of the UV treated culture to fresh medium containing a dose of a penicillin analogue which is detrimental to exponentially growing cells, but tolerable to non-growing cells, and ii) culturing the cells in said penicillin analogue comprising medium under conditions, which would promote exponential growth in the absence of penicillin or an analogue of penicillin such as ampicillin. The term "detrimental to exponentially growing cells" refers in the context of the present invention to compounds capable of reducing the exponential growth rate of the cells.

The term "tolerable" refers in the context of the present invention to compounds which are bacteriocritic.

In one embodiment, the methods of the present invention may comprise the steps of: i) culturing the progenitor cells or the Bifidobacterium sp. cell comprising a functional tetWgene or that has a Minimum Inhibitive Concen- tration of 4 microgram of tetracycline/ml or higher to obtain a culture of exponential growing cells, ii) transferring an aliquot of the cells obtained in step i) to fresh medium containing a chemical mutagen, iii) transferring the culture obtained in step ii) to one or more containers to form a 0.5 - 10 mm thick layer of culture, iv) subjecting the culture(s) of step iii) to a physical mutagen, v) culturing the mutated cells obtained from step iv) to obtain a culture of exponential growing cells, vi) transferring an aliqut ot bacteria from step v) to one or more Petri dishes containing a suitable agar growth medium, the aliquot of bacteria being selected to give single colonies vii) identifying those colonies from step vi) that have acquired antibiotic sensitivity by replica plating to petridishes with and without antibiotic, and viii) isolating and expanding the cells obtained in step vii).

The chemical and the physical mutagen may be as described in the paragraph describing chemical and physical mutagens which may be used in the methods of the present invention. It may be an advantage keeping or storing the antibiotica sensitive colonies obtained in step viii).

This procedure may also be described as 1) culture the progenitor cells to obtain a culture of exponential growing cells, 2) transfer an aliquot of the cells to fresh medium containing ethidium bromide (EtBr), 3) transfer the culture to one or more containers to form a 0.5 - 10 mm thick layer of culture, 4) subject the culture to a UV treatment, 5) culture the mutated cells to obtain a culture of exponential growing cells, 6) transfer an aliquot of bacteria to one or more petridishes to form single colonies, 7) identify those colonies that have acquired antibiotic sensitivity by replica plating to petridishes with and without antibiotic, and 8) isolate, expand and keep those antibiotic sensitive colonies identified as a new antibiotic sensitive strain.

In a further embodiment the culture obtained in step iv) or 4) may be subjected to an enrichment step for mutations comprising the steps of: iva) transfering an aliquot of the UV treated culture to a fresh medium containing a dose of a penicillin analogue which is detrimental to exponentially growing cells, but tolerable to non-growing cells, and ivb) culturing the cells in said penicillin analogue comprising medium under conditions which would promote exponential growth in the absence of penicillin or an analogue of penicillin such as ampicillin.

In the art, dilution tests are used to determine the minimum inhibitory concentrations (MICs) of antimicrobial agents, and these are the reference methods for antimicrobial susceptibility testing. In dilutions tests, microorganisms are tested for their ability to produce visible growth in suitable media, and the lowest concentration of an antimicrobial agent that inhibits the growth of a microorganism is defined as the MIC. The terms Minimum Inhibitory Concentration, Minimum Inhibitive Concentration and MIC may be used interchangeably in the context of the present invention. The MIC (Minimum Inhibitory Concentration) may be regarded as the lowest concentration of a particular compound which results in inhibition of visible growth, or as the minimum concentration of the antibacterial agent in a given culture medium below which bacterial growth is not inhibited.

Different assays exist for determining the MIC value for a particular compound. In the context of the present invention, the MIC value may in particular be determined according to the Etest susceptibility screening method described by Danielsen and Wind (2003). The Etest susceptibility screening method comprises the steps of: a) dipping a sterile cotton swab into a culture of a tetracycline sensitive strain to be tested, which has grown overnight, b) streaking the entire surface of a MRS agar plate (diameter: 8,5 cm) evenly in three directions with the cotton swab from step a) c) when the inoculum applied in step b) has dried, applying an E-test strip to the agar surface by help of a manual applicator with the MIC scale facing upwards d) inoculating the agar plate under anaerobically or microaerophilic conditions in an inverted position at 37°C overnight e) determining the MIC value by reading the value where the edge of the inhibition ellipse intersects the strip.

This method and the Etest strip are also described in EP 157 071 which is incorporated herein by reference.

Yet another method for determining the minimum inhibitory concentration is disclosed in FR-A-2 264 089, which is incorporated herein by reference.

By the expression "tetracycline-resistant" refers to a bacterium which has a minimum inhibitory concentration (MIC) of tetracycline of at least higher than 4ug/ml (EFSA, 2005), for instance at least 5 microgram/ml, such as at least 8 microgram/ml, including at least 10 microgram/ml or even at least 15 microgram tetracycline/ml. The MIC value may in particular be as determined by the Etest susceptibility screening method as described by Danielsen and Wind (2003).

Hence the Bifidobacterium sp. cell comprising a functional fefWgene may in particular have a Minimum Inhibitive Concentration as described above.

In the present context, the expression "sensitive to tetracyclines" refers to a bacterium which has a MIC of 1.5 microgram/ml or less, such as 1 microgram/ml or even less than 0.75 microgram/ml of a specific tetracycline of the group of tetracyclines. The MIC value may in particular be as determined by the Etest susceptibility screening method.

Specifically, the expression "sensitive to tetracycline" refers to a bacterium which has a MIC of 1.5 microgram tetracycline/ml or less, such as 1 microgram/ml or even less than 0.75 microgram tetracycline/ml. The MIC value may in particular be determined by the Etest susceptibility screening method. Hence, the Bifidobacterium sp. cell comprising an inactivated fefWgene may in particular have a Minimum Inhibitive Concentration as described above.

As demonstrated in example 12, until now all mutations that are characterized by a minimum inhibitive concentration (MIC) determined by the E-test, which is equal to or less than 1.5 μg tet/ml, contained a mutated tetW. This opens for a selection procedure, which result in the selection of tetracycline-sensitive Bifidobacteria strains which, with a high probability, contains an inactivated tetWgene. Thus, the methods of the present invention may further comprise a selection of tetracycline-sensitive mutants that are particularly likely to contain a mutated tetWgene. This selection method may comprise the following steps, thus the step b) in the method of the present invention described above may in particular further comprise the steps of: i) determining the minimum inhibitive concentration (MIC) of the bacteria by the Etest susceptibility screening method, ii) dividing the bacteria into two classes based on the result of the Etest susceptibility screening:

Class 1 : bacteria with a MIC of 1.5 μg/ml or less according to the Etest, and

Class 2: bacteria with a MIC over 1.5 μg/ml according to the Etest; and iii) identifying and expanding the antibiotica sensitive bacteria identified in ii) with a MIC of 1.5 μg/ml or less (Class 1).

It may be a further advantage to keep the antibiotica sensitive bacteria obtained in step iii).

"Tetracyclines" or "tetracycline group of antibiotics" refer to the group of bactiostatic an- tibiotics that are produced by Streptomyces species, and their related semisynthetic derivatives. Tetracyclines inhibit both Gram-positive and Gram-negative bacteria and rickettsiae. They are characterized by a mode of action which imply that the antibiotic reversibly bind to the 3OS ribosome and inhibit binding of aminoacyl-t-RNA to the acceptor site on the 70S ribosome. In addition to tetracycline itself, also terramycin, demeclo- cycline, meclocycline, doxycycline / doxycyclin, lymecycline, methacycline, minocycline, oxytetracycline, rolitetracycline, aureomycin as well as other chlortetracyclines are considered as members of the group of tetracyclines. Consequently, also a method wherein tetracyclines is an antibiotic selected from the group consisting of but not limited to tetracycline, terramycin, demeclocycline, meclocycline, doxycycline/doxycyclin, lymecy- dine, methacycline, minocycline, oxytetracycline, rolitetracycline, aureomycin and other chlortetracyclines is an embodiment of the present invention.

The preferred type of tetracyclines is tetracycline. As mentioned, it required several attempts before the present method was developed. It is contemplated that it is the combined action of both a chemical and a physical mutagen, e.g. ethidium bromide and ultraviolet light, which increases the chance of a successful mutation of the fefWgene.

To further increase the likelihood of success, the culture or the Bifidobacterium sp.cell comprising a functional fefWgene or having a MIC value of 4 microgram tetracycline/ml or higher, may subsequent to the mutation step, i.e. the step of subjecting said culture or cells to a chemical and physical mutagen, be subjected to an enrichment step for muta- tions comprising the steps of: a) transferring an aliquot of the UV treated culture to fresh medium containing a dose of a penicillin analogue which is detrimental to exponentially growing cells, but tolerable to non-growing cells, and b) culturing the cells in said penicillin analogue comprising medium under conditions which would promote exponential growth in the absence of a penicillin analogue.

Considering that such an "ampicillin selection procedure" is well established and has been frequently used for gram-negative bacteria since 1972 (Miller 1972), it is surprising that the "ampicillin selection procedure" to the best of our knowledge has not previously been used in a mutation protocol directed against gram-positive Bifidobacteriaceae Although some Bifidobacteriacea may grow under aerobic conditions, it is considered advantageous when the culture is performed at a reduced oxygen tension, e.g. by supplying the growth medium with cysteine hydrochloride as described in example 1.

In general, the dual mutagenic approach of the present invention is considered more forceful scale than when the mutagens are used individually.

The chemical mutagen may in principle be any chemical compound capable of mutagenizing nucleic acids, in particular DNA. In particular the chemical mutagen may be an intercalating UV-absorbing mutagen, i.e. a chemical compound capable of both intercalating with nucleic acids, such as DNA, and of absorbing UV-light. Without being bound by any theory, the inventor of the present invention believes that by the combination of intercalating UV-absorbing compounds as chemical mutagens and UV irradiation as the physical mutagen, it is possible to obtain a certain degree of sequence-specificity with regard to mutation of a nucleic acid sequence, such as DNA. For example ethidium bromide (EtBr) which is an intercalating UV-absorbing compound does not usually inter- calate randomly into DNA. Generally, the amount of EtBr which intercalates into the DNA depends on e.g. the degree of supercoiling of the DNA. As the degree of super- coiled DNA, at least in eukarγotes, correlates with the expression level of a particular gene, it is contemplated that this may result in a certain degree of sequence-specificity with regard to where the EtBr intercalates with the DNA. The presence of intercalated EtBr in a DNA sequence generally results in mutation(s) of the DNA sequence at the places where the EtBr is intercalated when said sequence is exposed to UV light. Furthemore, EtBr is generally to intercalate with in stretches of polydA-polydT tract DNA sequences or at least the ratio of EtBr intercalation with such sequences is low compared to other sequences. Examples of suitable intercalating UV-absorbing compounds include, but are not limited to ethidium bromide (EtBr), ethidium, proflavine, daunomycin, adriamycin, actinomycin, ellipticine, tilorone, m-AMSA, mithramycin, netropsin, irehdiamine A, anthramycin, step- tonigrin, bleomycin, ditercalinium, triostin and echinomycin. Other examples of such suitable compounds are given in US 5,391 ,723, which is incorporated herein by refer- ence.

The physical mutagen of the present invention may in a particular embodiment be a non-ionizing radiation with a wavelength shorter than 800 nm. An example of such a physical mutagen is UV radiation. Hence, in one embodiment of the present invention, the chemical mutagen is an interca- lating UV absorbing compound, such as any of the examples mentioned above, and the physical mutagen is a non-ionizing radiation with a wavelength shorter than 800 nm, such as UV radiation. In a further embodiment, the chemical mutagen is EtBr and the physical mutagen is UV radiation. As illustrated in example 1 , the combined action of EtBr and exposure to UV light con- siderably reduces the viability of the cells immediately after the EtBr-UV treatments. It is contemplated that such forceful dual approach may be the reason that it has been possible to achieve an effective inactivation of fefWgene in Bifidobacteriace. Thus in one important embodiment of the present invention, the UV-treatment is adjusted to result in a reduction of the number of living cells as measured by Colony Forming Units (CFUs) to less that 20%, such as less than 15% or even less that 10% relative to the number of the CFUs of the culture immediately before the UV-treatment. This adjustment of the UV-treatment may in one embodiment be performed in step iv) of the method.

In a preferred embodiment, the EtBr concentration is adjusted to be between 10 and 30 microgram/ml. In further embodiments, the penicillin analogue used in the "ampicillin enrichment procedure" is ampicillin which in particular may be used at a dose of 50-300 microgram/ml in the medium, in particular this dose of ampicillin may be used together with a EtBr concentration of 10-30 microgram/ml

5 Resistance to tetracycline and oxytetracycline has been observed in strains of Bifidobacterium catenulatum, Bifidobacterium longum, Bifidobacterium pseudocatenulatum, Bifidobacterium asteroids, Bifidobacterium infantis, Bifidobacterium lactis, Bifidobacterium animalis and subspecies thereof (Yazid (2000), Lim (1983), Scott (2000), this study). TetWhas been observed in tetracycline resistant strains of Bifidobacterium

10 longum, Bifidobacterium pseudocatenulatum, Bifidobacterium bifidum, Bifidobacterium lactis (Scott et al. 2000, Moubareck et al. 2005). However, resistance to tetracycline is not characteristic of probiotic Bifidobacterium strains. Moubareck (2005) reports that probiotic Bifidobacteria in general appear to be more susceptible to antibiotics, and the two well-known probiotic Bifidobacteria, Bifidobacterium animalis supsp. lactis strain Bb-

15 12® and DR10™ have been reported to be tetracycline sensitive (Zhou et al. 2005). Also, Moubareck (2005) did not find tetW in Bifidobacterium animalis. Surprisingly however; the present study has disclosed that also probiotic Bifidobacterium strains, including probiotic Bifidobacterium animalis strains such as Bifidobacterium animalis supsp. lactis strain Bb-12® and DR10™, contain a functional tetW rendering the bacteria resis-

20 tant to tetracycline.

Thus, in presently preferred embodiments, the bacterial species is selected from the group consisting of Bifidobacteriacea that contains a functional tetW rendering the bacteria resistant to tetracycline. In a further preferred embodiment, the tetracycline-

25 resistant bacterial progenitor strain is a probiotic strain. Similarly, the Bifidobacterium sp. cell comprising a functional fefWgene or that has a MIC value of 4 microgram tetracy- cline/ml or higher may be a probiotic cell.

The mutant Bifidobacterium sp. cell comprising an inactivated fefWgene or that has a MIC value of 1.5 microgram tetracycline/ml or less may also be a probiotic cell.

30 In the context of the present invention, the term "probiotic" is to be understood as "Live microorganisms which when administered in adequate amounts confer a health benefit on the host" (FAO / WHO 2002).

In particular, probiotic strains may be strains which are able to survive the passage of the esophagus and the stomach and furthermore able to survive the exposure to bile

35 acid that occur in the upper part of the intestine. Consequently a potential probiotic bac- terium is expected to survive exposure to the gastric juice in the stomach (example 9) and further exhibit resistance to bile salts (example 10). The placebo strain for such studies may in particular be strains which do not have a probiotic effect; more particularly strains which further do not have a pathogenic effect. Other test for determining whether or not a strain is regarded as being probiotic include During the recent years, documentation of probiotic properties of Bifidobacteria and other lactic bacteria has accumulated. In general, the probiotic activity is associated with specific strains. The previously mentioned Bifidobacterium animalis strain Bb-12® as well as Bifidobacterium lactis strain HN019 have been reported as probiotic (WO 01/97822, WO 03/099037, Zhou et al. (2005), US 6379663).

Bifidobacterium species which are useful in the present invention include but are not limited to Bifidobacterium adolescentis, Bifidobacterium animalis, Bifidobacterium asteroids, Bifidobacterium bifidum, Bifidobacterium breve, Bifidobacterium catenulatum, Bifi- dobacterium infantis, Bifidobacterium lactis, Bifidobacterium longum and Bifidobacterium pseudocatenulatum and subspecies thereof.

The invention is not, however, limited to these above mentioned particular Bifidobacteri- acea. The person skilled in the art would recognise those Bifidobacteriacea which may be useful in the method according to the invention, as well as other probiotic bacteria which contain a functional tet W rendering them resistant to tetracyclines.

In the preferred embodiment, the progenitor strain or cell, the Bifidobacterium sp. cell which comprises a functional fefWgene or the Bifidobacterium sp. cell which has a MIC of 4 microgram tetracycline/ml or higher, is a strain of Bifidobacterium animalis subspe- cies lactis. In particular, said cell or strain is a cell or strain the Bifidobacterium animalis subspecies lactis strain CHCC5445 (Bb-12®), deposited on September 30 , 2003 according to the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure with the Deutsche Sammlung von Mik- roorganismen und Zellkulturen under accession number DSM 15954, or the Bifidobacte- rium animalis subspecies lactis strain CHCC7158, deposited on April 28 , 2005 according to the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure with the Deutsche Sammlung von Mikro- organismen und Zellkulturen under accession number DSM17280. It is noteworthy to emphasise that the nomenclature of Bifidobacterium animalis subspecies lactis has changed over the years.

Initially, the Bifidobacterium Bb-12® strain was described as a Bifidobacterium bifidum. Subsequently it was found that Bifidobacterium animalis was more correct, although the strain is not a typical Bifidobacterium animalis. The strain differs in several aspects from Bifidobacterium animalis as described by Meile et al (1997), who suggested establishing a new species, Bifidobacterium lactis. This specie's name was later validated on list no. 62 in IJSB (1997). The species status of Bifidobacterium lactis has been discussed since Meiles publication. Recently, Cai et al. (2000) published DNA-DNA hybridisation results, which showed that Bifidobacterium lactis did not differ enough from Bifidobacterium animalis to allow species status. Based on these results, the International Committee on Systematic Bacteriology, Subcommittee on the taxonomy of Bifidobacterium, Lactobacillus and related organisms has decided that Bifidobacterium lactis cannot be acknowledged as a valid species (Minutes, IJSEM, 2001). Since then, a polyphasic taxonomic analysis has been done and published leading to the creation of two subspecies within Bifidobacterium animalis (Masco et al_, 2004). Bb-12® belongs to one of the subspecies, B. animalis subsp. lactis. Based on DNA fingerprints, it appears to us that also the well-known Bifidobacterium strain DR10™ should correctly be designated as B. animalis subsp. lactis. In the literature strain DR10™, is also referred to as Bifidobacterium lactis HN019 (Zhou 2005) and HOWARU™ Bifido (www.danisco.com).

As illustrated in example 2, the method of the present invention may result in two classes of novel antibiotic-sensitive isolates one class which express an intermediate level of tetracycline sensitivity, i.e. isolates with a MIC ranging between 2 and 4 μg tet- racycline/ml, and isolates with a MIC lower than 1.5 μg tetracycline/ml such as 0.75 or even 0.5 μg tetracycline/ml. Until now, we have only identified isolates with an inactivated tetW in isolates with a MIC lower than 1.5 μg tetracycline/ml, and in all cases we used Bifidobacteriacea having a MIC larger than 10 microgram tetracycline/ml as pro- genitor cells. Thus, a preferred embodiment of the present invention is a method of isolating a tetracycline sensitive strain of Bifidobacterium sp. (Bifidobacteriacea) from a tet- racycline-resistant bacterial progenitor strain wherein the Minimum inhibitive Concentration (MIC) of tetracycline of the progenitor strain is at least 10 microgram tetracycline/ml and the MIC of the antibiotic sensitive strain is 1.5 microgram tetracycline/ml or less. The progenitor strain may be a Bifidobacterium sp. cell comprising a functional tetW gene or that has a MIC value of 4 microgram tetracycline/ml or higher, and the antibiotic sensitive strain may be a mutant Bifidobacterium sp. cell comprising an inactivated tetW gene or that has a MIC value of 1.5 microgram tetracycline/ml or less.

As the tetracycline group of antibiotics shares the same mode of action, it is contemplated that the inactivation of tetW in general will result in a sensitivity shift to any of the tetracycline group of antibiotics of a size similar to the shift observed with tetracycline. Consequently, an embodiment of the invention is a method of isolating a strain of Bifidobacterium sp. (Bifidobacteriacea) that is sensitive to one or more of tetracyclines from a bacterial progenitor strain that is resistant to one or more of the tetracyclines and wherein the Minimum inhibitive Concentration (MIC) of said antibiotic of the progenitor strain is at least 10-fold higher than the MIC of the antibiotic sensitive strain. The progenitor strain may be a Bifidobacterium sp. cell comprising a functional fefWgene or that has a MIC value of 4 microgram tetracycline/ml or higher, and the antibiotic sensi- tive strain may be a mutant Bifidobacterium sp. cell comprising an inactivated fefWgene or that has a MIC value of 1.5 microgram tetracycline/ml or less.

Examples of the tetracycline group of antibiotics are represented by the group of antibiotics comprising tetracycline, terramycin, demeclocycline, meclocycline, doxycycline / doxycyclin, lymecycline, methacycline, minocycline, oxytetracycline, rolitetracycline, aureomycin and other chlortetracyclines.

To the best of our knowledge, until now all probiotic strains of Bifidobacterium animalis subs, lactis, and a substantial number of other Bifidobacteriacea carry a functional tetW determinant rendering them resistant to tetracycline. The inventor of the present invention surprisingly discovered that it was possible to provide Bifidobacteriacea that carry an inactivated tet W determinant.

As illustrated in the examples, it is indeed possible to obtain variants of known probiotic strains of Bifidobacterium sp. that contains a mutated, chromosomally encoded tetW rendering the strain sensitive to tetracyclines. The provision of such new strains is considered the most preferred embodiment of the present invention. Hence in a further embodiment, the present invention relates to a Bifidobacterium sp. cell comprising an inactivated tetWgene. This cell may in particular have a Minimum Inhibitive Concentration of 1.5 microgram tetracycline /ml.

In a further embodiment, the Bifidobacterium sp. cell the inactivated fefWgene may be located on the chromosome of said cells.

In another embodiment, the present invention also relates to a Bifidobacterium sp. cell which has a Minimum Inhibitive Concentration of 1.5 microgram tetracycline/ml.

In a further embodiment, the present invention relates to a Bifidobacterium sp. cell containing a mutated, chromosomally encoded tet W rendering the cell sensitive to tetracyclines obtainable by a method of the present invention.

The present invention also relates to a Bifidobacterium cell which is sensitive to tetracy- dines due to a mutation in tetW, said Bifidobacterium cell being derived from a progenitor cell which is resistant to tetracyclines due to the presence of a tetW gene located on the chromosome.

The new strain or cell may in principle be a variant or mutation of any Bifidobacterium that carries a chromosomally encoded tetW rendering the strain resistant to tetracyclines. Suitable cells may be selected from the group of Bifidobacteriacea comprising Bifidobacterium longum, Bifidobacterium pseudocatenulatum, Bifidobacterium bifidum, Bifidobacterium lactis, Bifidobacterium animalis and subspecies thereof. In particular, cells classified as Bifidobacterium animalis subspecies lactis are preferred.

Reference to tetracycline in relation to a Bifidobacterium sp. cell of the present invent- tion include those described in relation to the methods of the present invention. Similarly, the progenitor cell may be any of those previously mentioned in relation to a progenitor cell useful in a method of the present invention. In general, new bacterial strains having a Minimum inhibitive Concentration (MIC) of antibiotic which is at least 10-fold lower than the MIC of the antibiotic resistant progenitor strain are preferred.

Hence, the Minimum inhibitive Concentration of antibiotic (MIC) of the progenitor cell may be at least 10-fold higher than the MIC of the antibiotic sensitive cell. In particular, the Minimum inhibitive Concentration (MIC) of tetracycline of the progenitor cell may be at least 10 microgram tetracycline/ml and the MIC of the antibiotic sensitive strain cell may be 1 microgram tetracycline /ml or less.

Preferred Bifidobacterium sp. cells of the present invention may be those having a MIC that is 1.5 microgram tetracycline/ml or less, such as 1 microgram/ml or even less than 0.75 microgram tetracycline/ml. The MIC value may in particular be as determined by the Etest susceptibility screening method.

Such strains which harbor a mutated tetW are particularly preferred embodiments of the invention.

The inactivating mutation of the fefWgene that renders the new strains sensitive to tetracyclines may typically be described in relation to the tetWgene sequence of the rele- vant progenitor cell.

As described in the examples suitable tetracycline-sensitive strains with an inactivated tetW can be achieved by introducing specific mutations in the fefWgene.

In one preferred embodiment of the invention, an "opal" stop codon has been introduced in the tetW by changing a part of the chromosomally encoded tetW characterized by the sequence TCG CTG GGA TAC JJG AAC CAG AGT [SEQ ID 1] to TCG CTG GGA TAC TGA ACC AGA GTT [SEQ ID 2], the deleted base in the functional tetW is indicated by underscoring. Thus, a Bifidobacterium cell which comprises the sequence: GGA TAC TGA ACC [SEQ ID 3] or [ATACTGAA] in its fefWgene is a preferred em- bodiment of the present invention. We also observed that the fefWgene could be inactivated, and result in sensitivity to tetracycline, by changing the part of chromosomally encoded tetW which comprises the sequence: CAG AGC GTG GTT CAG TCT GTT CGG [SEQ ID 4] to CAG AGC GTG GTT TAG TCT GTT CGG [SEQ ID 5]. This mutation introduces an "amber" stop codon in tetW, and the mutated base in the functional tetW is underscored. Such a Bifidobacterium which comprise the sequence: GTG GTT TAG TCT [SEQ ID 6] or [GGTTTAGT] in its fefWgene is another preferred embodiment of the present invention. A bacterial strain or the Bifidobacterium sp. cell of the present invention wherein the inactivated or mutated tetWgene comprises at least one sequence selected from the group consisting of but not limited to SEQ ID NO:3 [GGA TAC TGA ACC], [ATACTGAA], SEQ ID NO: 6 [GTG GTT TAG, TCT], [GGTTTAGT], SEQ ID NO: 27 [AC CAG CGT TTT C] and [CAGCGTTT] is also an embodiment of the present invention.

The introduction of the "opal" and the "amber" stop codons into the protein coding region of the fefWgene represents two very different molecular events. I the case of the "opal" mutation, a base was deleted, whereas in the case of the amber, a base was mutated (in casu from C to T pair, i.e. a base transition).

It should be emphasized that the tetW of a Bifidobacterium may be inactivated by other types of mutations in other sites of tetW. This is illustrated by the Bifidobacterium mutant strain Bb-12Tet-S180 wherein the fefWgene comprise SEQ ID NO: 27 [AC CAG CGT TTT C] which represents a single-base transversion of an A to a C in position #2731 in SEQ ID 22; and the DR10Tet-S33 and Bb-12Tet-S79 which comprise multiple mutations in tetW. DR10Tet-S33 comprise two mutations in tetW described by SEQ ID NO: 28 [CG CCC TGC CAC A] (or [CCCTGCCA]) and SEQ ID NO: 29 [AT ATT GTC ATC A] (or [ATTGTCAT]), and Bb-12Tet-S79 comprise three mutations described by SEQ ID NO: 30 [TA GAC GAT GGA A] (or [GACGATGG]), SEQ ID NO: 31 [CG GTC CGG GTA A] (or [GTCCGGGT]) and SEQ ID NO: 32 [CT GAT CCG GCC TT] (or [GATCCGGC]). Thus in one embodiment, the Bifidobacterium sp. cell of the present in- vention may be a cell wherein the inactivated or mutated fefWgene comprises one of the above mentioned combinations of sequences.

Thus, the Bifidobacterium sp. cell according to the present invention may be a cell, wherein the inactivated or mutated tetW gene comprises at least one sequence selected from the group of SEQ ID 3 [GGATACTGAACC], SEQ ID NO: 6 [GTGGTTTAGTCT], SEQ ID 25 [ATACTGAA], SEQ ID NO: 27 [ACCAGCGT TTTC], SEQ ID 28 [CGCCCTGCCACA], SEQ ID 29 [ATATTGTCATCA], SEQ ID 30 [TAGACGATGGAA], SEQ ID 31 [CGGTCCGGGTAA], SEQ ID 32 [CTGATCCG G CCTT], [CAGCGTTT], [GACGATGG], [GTCCGGGT], [ATCCGGCC], [CCTGCCAC], [TTGTCATC], [GGTTTAGT], [GTGGACCG], [CGCCCATT] and [TCCGGCCC].

In particular, the Bifidobacterium sp. cell according to the present invention may be a cell wherein the inactivated or mutated tetW gene comprises the sequences [CCTGCCAC] and [TTGTCATC]. In another embodiment, the Bifidobacterium sp. cell according to the present invention may be a cell wherein the inactivated or mutated tetWgene comprises the sequences [GACGATGG], [GTCCGGGη and [ATCCGGCC].

Insofar as the Bifidobacterium strain contains a mutated, chromosomally encoded tetW rendering the strain sensitive to tetracyclines and which is obtainable by the method of the present invention, the resulting tetracycline sensitive strains are embodiments of the present invention.

A very important indication of whether a mutated tetracayline sensitive strain is particularly likely to contain a mutated fefWgene, is to determine minimum inhibitive concentration (MIC) of the bacteria by the Etest susceptibility screening method. As demonstrated in example 12, mutated strains may be classified in two classes: Class 1 : strains with a MIC of1.5 μg/ml or less; and Class 2: strains with a MIC > 1.5 μg/ml. This is used in an embodiment of the method of isolating strains which comprise the steps of: a) determining the minimum inhibitive concentration (MIC) of the bacteria by the Etest susceptibility screening method, b) based on the result of the Etest susceptibility screening, dividing the bacteria into two classes: Class 1 : bacteria with a MIC of 1.5 μg/ml or less according to the Etest, and

Class 2: bacteria with a MIC over 1.5 μg/ml according to the Etest; and c) identifing and expanding those antibiotica sensitive bacteria identified in b) to belong to class 1.

In a further embodiment step c) may include keeping the antibiotica sensitive bacteria. In particular step c) may be identifying, expanding and keeping those antibiotica sensitive bacteria identified in b) to belong to class 1 as a new antibiotica sensitive strain.The most preferred embodiment of the present invention is the bacterial strain or the Bifidobacterium sp. cell of the present invention, which is identified as Bifidobacterium ani- malis subspecies lactis strain CHCC8902 (Bb-12Tet-S139) and deposited on April 28, 2005 according to the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure with the Deutsche Sammlung von Mikroorganismen und Zellkulturen under accession number DSM 17281. This tetracycline sensitive strain contains the "opal" mutation in its tetW. This strain is particularly preferred because it is a mutation of the well-known probiotic Bifidobacterium strains Bb-12®. Furthermore, CHCC8902 contains a single base deletion in tet W characterized in a relatively low reversion rate of less than 1.6 x 10^~9 making it particularly suitable for ingestion in large numbers (see Example 4). As illustrated in example 9 and 10, the tetracycline sensitive Bb-12Tet-S139 strain has preserved the characteristics of a probiotic strain. Thus, in a particularly preferred embodiment of the present invention, the tetracy- cline-sensitive bacterial strain or the Bifidobacterium sp. cell of the present invention is a probiotic strain.

Another preferred embodiment of the present invention is a bacterial strain or the Bifidobacterium sp. cell of the present invention which is identified as Bifidobacterium animalis subspecies lactis strain CHCC9070 (DR10Tet-S9X) and deposited on April 28, 2005 according to the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure with the Deutsche Sammlung von Mikroorganismen und Zellkulturen under accession number DSM17282. This tetracycline sensitive strain contains the "amber" mutation in its tetW. This strain is also pre- ferred because it is a mutation of the well-known probiotic Bifidobacterium strain

DR10™ (CHCC7158). CHCC9070 (DR10Tet-S9X) contains a single base transition in tetW. As anticipated by the existing literature on base transitions, the reversion rate is higher than e.g. deletion mutants. In the case of CHCC9070 which contains the back mutation rate 1.8 x 10^~8. Although CHCC9070 is more prone to reversion than CHCC8902, the strain is still relatively stable and consequently suitable for ingestion.

As mentioned, some Bifidobacteria can serve as probiotics i.e. as non-pathogenic organisms, which have health benefits when taken orally in foods or capsules. Common targets of probiotic action are intestinal disorders (e.g. travellers diarrhea, antibiotic as- sociated diarrhea) or intestinal symptoms (bloating, flatulence, discomfort). Yet, a wider range of benefits (e.g. anticholesterolemic, anticarcinogenic and immunostimulatory properties) is also discussed in the probiotic literature.

Thus in a further embodiment, the present invention relates to the use of a Bifidobacte- hum sp. cell of the present invention for the preparation of an ingestible material or a bacterial culture.

Thus in a further embodiment, the Bifidobacterium sp.cell of the present invention may be for the use as a probiotic. In particular the Bifidobacterium sp.cell of the present invention for the use as a probiotic may be in the form of an ingestible material.

In another embodiment, the present invention also relates to a method of treating a mammal by administering a Bifidobacterium sp.cell according to the present invention.

In particular the Bifidobacterium sp.cell may be given in the method as an ingestible material.

The terms "gastrointestinal tract" or "intestinal" are in the present context used interchangeably and relate to both the upper and lower gastrointestinal tract which include the mouth, the oesophagus, the stomach, the small intestines including the duodenum, the jejunum and the ileum, and the large intestines comprising colon and caecum.

The bacterial culture may in a further embodiment be further processed.

The bacteria, i.e. the Bifidobacterium sp. cell, of this invention may be given in the form of a fermented food product or in a dosage forms formulated as a tablet (including chew- able tablets), a capsule (of either the hard or soft type), a powder, a granulate, a liquid preparation, a suspension, a dried oral supplement, a wet oral supplement, a dry tube feeding formulation or wet tube feeding formulation.

In one embodiment, the ingestible material is a fermentated food or feed product prepared by use of the Bifidobacteria of the present invention. Hence in another embodi- ment the present invention also relates to a food or feed product comprising a bacterial cell or strain according to the present invention, i.e. a Bifidobacterium sp. cell according to the present invention.

The fermentated food or feed product may be further processed. In a number of situations, it has been reported that bacteria produce health promoting compounds during fermentation. In such cases, it might be advantageous to fractionate and/or up concentrate fractions of the fermented food product. One can even imagine that it, in certain situations, would be valuable to further process the fermented food product by pasteurization, even though the beneficial Bifidobacteria are inactivated by such procedure. However, in general it is considered beneficial that the ingestible material comprise live Bifidobacteria in an amount from about 10⁵ cfu/g to about 10¹² cfu/g ingestible material, since living cells are a prerequisite for obtaining the probiotic effect.

It is contemplated that the Bifidobacteria of the present invention can be used for the preparation of a wide range of ingestible materials such as milk, curd, milk based fermented products, acidified milk, yoghurt, frozen yoghurt, milk powder, milk based powders, milk concentrate, cheese, cheese spreads, dressings beverages, ice-creams, ice- lollies or popsicles, fermented cereal based products, infant formulae and soybean milk.

A further important embodiment of the present invention is the use of the Bifidobacteria of the present invention to prepare a composition for the treatment or prevention of a disease, syndrome or condition, or for improving digestion of nutrients, or for improving the general health status of a human being or a vertebrate animal.

Since Bifidobacteria in general are considered as probiotic organisms (Yazid, 2000) the use of a Bifidobacteria of the present invention as a probiotic is a preferred embodiment. The probiotic composition of the present invention can be any ingestible material selected from the group consisting of milk, curd, milk based fermented products, acidified milk, yoghurt, frozen yoghurt, milk powder, milk based powders, milk concentrate, cheese, cheese spreads, dressings beverages, ice-creams, fermented cereal based products, infant formulae, tablets, liquid bacterial suspensions, dried oral supplement, wet oral supplement, dry tube feeding or wet tubefeeding that are produced by use of the Bifidobacteria of this invention.

In a further embodiment, the composition further comprises a pharmaceutically acceptable carrier. As used herein, the term "pharmaceutically acceptable carrier" means one or more solid or liquid filler diluents, or one or more encapsulating substances which are suitable for administration to a human or an animal and which is/are compatible with the probiotically active organisms. The term "compatible" relates to components of the pharmaceutical composition which are capable of being commingled with the probiotic in a manner enabling no interaction because it would substantially reduce the probiotic efficacy of the organisms selected for the invention under ordinary use conditions. Pharmaceutically acceptable carriers must be of a sufficiently high purity and a sufficiently low toxicity to render them suitable for administration to humans and animals being treated.

In useful embodiments, the ingestible material according to the invention is suitable for preventing or treating a disease, syndrome or condition selected from the group consist- ing of antibiotic-associated disorders, gastroenteritis, diarrhea including traveller's diarrhea and acute infantile diarrhea, lactose intolerance, gastrointestinal infections and colonization of the gastrointestinal tract by pathogenic bacteria including Helicobacter pylori and Clostridium difficile, irritable bowel syndrome (IBS), inflammatory bowel disease (IBD) and other immunomodulative syndromes, colonic cancer, urogenital infec- tions and tumours, vaginal infections, allergy (especially atopic eczema), vaccination, cholesterolemia and hypertension.

In further useful embodiments, the ingestible material according to the invention is suitable for preventing or treating infections with pathogens such as e.g. Heliobacter pylori, Campylobacter pylori, Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pyogenes, Streptococcus pneumoniae, Enterococcus faecalis, Hemophilus influenzae, Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, Citrobacter freundii, Serratia marcescens, Pseudomonas aeruginosa and Pseudomonas maltophilia, Salmonella sp. and fungi such as Candida albicans and Aspergillus fumigatus, and combina- tions of these species.

In recent years, rotaviruses and other enteric viruses have been identified as a major cause of infectious diarrhoea. Interestingly, both Bifidobacterium Bb-12® and HN019 (DR10™) have been shown to effectively prevent or treat infections also with these pathogens. Thus, in useful embodiments, the ingestible material according to the invention is used for preventing or treating infections with rotaviruses and other enteric viruses.

It may be useful to combine two or more of the above assumingly probiotically active organisms, such as e.g. a preparation comprising a Lactobacillus species and a Bifidobacterium species.

Performance of the mutant strains and their benefits to human The Bifidobacterium animalis subsp. lactis Bb-12® (CHCC5445), is an extremely important strain for the health and well being of mammals due to its probiotic capabilities (e.g. immune stabilizing effect in humans, controlling of a balanced microflora in the digestive tract thereby reducing or acting as inhibitors of various epidemiologic syndromes, etc.). Also the Bifidobacterium animalis subsp. lactis HN019 (DR10™, CHCC7158), has an impressive record of probiotic activity. Although both of these strains harbours an active gene encoding resistance to tetracycline, the most prominent bacterial antibiotic resistance found in nature (Chopra and Roberts, 2001), both have for many years been used in food production, and to our knowledge without causing any harm. On the con- trary, only positive effects have been ascribed to the use of these strains. However, the fact that both strains contain an active tetW in their genome does possess the theoretical possibility of transferring the tetracycline resistance to other - and perhaps harmful bacteria in the human digestive system. The risk of this increase if ingested donor bacteria survive in the gut in large numbers, as is the case with the typical use of probiotic bacteria. Inactivation of the fefWgene in the two variants, as it has been demonstrated here, eliminates the risk of a horizontal transfer of functional antibiotic resistant genes. Apart from the lesion in the tetW, the two tetracycline sensitive strains are probably isogenic with their mother strains, as suggested under Example 5 and Example 6. Thereby it can be assumed that the two tetracycline sensitive strains possess most if not all the features that make Bb-12® and HN019 (DR10™) probiotic.

In addition, laboratory tests involving two-dimensional gel-electrophoresis for further characterization of the mutant strains are being performed to verify the isogenic back- ground with the wild type strains.

Conclusion

1) - inactivation of the tetracycline resistance gene, tetW, from Bifidi bacterium animalis ssp lactis Bb-12® and Bifidibacterium animalis ssp lactis HN019 (DR10™) was established by a combination of the intercalating mutagen, ethidium bromide, and successive ultra violet irradiation. 2) - five of the resulting tetracycline sensitive isolates originating from Bb-12 ® and from HN019 (DR10™) were incapable of growing in MRS broth with tetracycline in a concentration above 1.5 μg/ml.

3) - characterization of one of the mutant isolates, Bb12Tet-139 (a derivative of CHCC5445) demonstrated a frame shift at nucleotide position #2722 in the fefWgene immediately resulting in an opal stop codon 170 amino acids short of the gene product. In the other mutant, DR10Tet-S9X (a derivative of CHCC7158) an amber stop codon was introduced (nucleotide position # 1741), 498 amino acids short of the gene product.

4) - the reversion rate for Bb12Tet-S139 is less than 1.6 x 10^~9 and the back muta- tion rate for DR10Tet-S9x is 1.8 x 10-⁸.

5) - growth, acidification rates DNA-profile and the transcriptome (Example 6) of the tet W mutants were not different to the respective wild types strains.

6) - analyses of the mutant isolates did not disclose any re-arrangements or modifications, but for tetW, of the genomic DNA as judged from DNA fingerprinting- and transcriptomics analyses

7) - experiments show that Bb12Tet-139 have preserved many of the probiotic characteristics of Bb-12 ®.

Bifidobacteria and other lactic acid bacteria are commonly used as starter cultures serv- ing a technological purpose in the production of various foods. The most well known industry using starter cultures is the dairy industry, but starter cultures are also used in other industries, e.g. in the meat processing industry. Thus, one embodiment of the present invention is the use of a Bifidobacterium strain according to the invention for the preparation of a starter culture. Starter cultures may be provided as frozen or dried starter cultures in addition to liquid starter cultures. In a further embodiment the starter culture may be freeze dried, spray dried or fluid bed dried.

A starter culture composition according to the invention typically comprises bacteria of a concentration of viable cells, which is in the range of 10⁴ to 10¹² cfu per gram of the composition. A convenient method of making a frozen starter culture comprising the fol- lowing steps: 1. culturing a bacterial strain according to present invention, 2. harvesting the propagated cells to provide a concentrated bacterial culture, 3. freezing the bacterial material to get frozen material, and 4. packing the freeze dried material in a suitable container. Similarly, a convenient method of making a freeze dried starter culture comprises the following steps: 1. culturing a bacterial strain according to claims present in- vention, 2. harvesting the propagated cells to provide a concentrated bacterial culture, 3. freezing the bacterial material to get frozen material, 4. sublimation of water from the frozen material, and 5. packing the freeze dried material in a suitable container. Also, a spray/fluid bed dried starter culture is contemplated. The freezing of the bacterial material may conveniently be performed by dripping the concentrated culture into liquid nitro- gen and collecting the frozen material.

As disclosed in WO 2005/003327 A1 , it is beneficial to add certain cryoprotective agents to a starter culture. Thus, a starter culture composition according to the present invention may comprises one or more cryoprotective agent(s) selected from the group con- sisting of inosine-5'-monophosphate (IMP), adenosine-5'-monophosphate (AMP), gua- nosine-5'-monophosphate (GMP), uranosine-5'-monophosphate (UMP), cytidine-5¹- monophosphate (CMP), adenine, guanine, uracil, cytosine, adenosine, guanosine, uridine, cytidine, hypoxanthine, xanthine, hypoxanthine, orotidine, thymidine, inosine and a derivative of any of such compounds.

The invention presented in the form of claims

Preferred aspects and embodiments of the invention may be presented in the form of so-called claims. This is given below.

1. A method of isolating a strain of Bifidobacterium sp. (Bifidobacteriacea) containing a mutated tetW on its chromosome, said mutation renders the strain sensitive to tetracyclines and said strain is isolated from a tetracycline-resistant bacterial progenitor strain wherein the antibiotic resistant phenotype is caused by the expression of tetW stably integrated in its chromosome, said method comprising subjecting the cells to a chemical mutagen and a physical mutagen.

2. The method according to claim 1, wherein the chemical mutagen comprises ethidium bromide (EtBr) and the physical mutagen is UV.

3. The method according to claims 1 or 2, wherein the tetracycline-resistant bacterial- progenitor strain is selected from the group of strains consisting of Bifidobacterium animalis subspecies lactis strain CHCC5445 (Bb-12®), deposited on September 30 , 2003 with the Deutsche Sammlung von Mikroorganismen und Zellkulturen under ac- cession number DSM 15954, and, Bifidobacterium animalis subspecies lactis strain CHCC7158, deposited on April 28 , 2005 with the Deutsche Sammlung von Mikroorganismen und Zellkulturen under accession number DSM 17280.

4. The method according to claims 1 to 3, wherein the method comprise a selection of tetracyclines-sensitive mutants that are particularly likely to contain a mutated tetW gene, said selection method comprisin the steps of: a) determining the minimum inhibitive concentration (MIC) of the bacteria by the Etest susceptibility screening method, b) dividing the bacteria into two classes based on the result of the Etest susceptibil- ity screening:

Class 1 : bacteria with a MIC of 1 ,5 μg/ml or less according to the Etest, and Class 2: bacteria with a MIC over 1 ,5 μg/ml according to the Etest; and c) identifying, expanding and keeping those antibiotica sensitive bacteria identified in b) with a MIC of 1,5 μg/ml or less (Class 1) as a new antibiotica sensitive strain. 5. The method according to claim 4, wherein tetracyclines is tetracycline.

6. The method according to claims 1 to 5, wherein the tetracycline-resistant bacterial progenitor strain is a probiotic strain.

7. The method according to claims 1 to 6, wherein the tetracycline-sensitive bacterial strain is a probiotic strain.

8. The method according to claim 1 to 7, wherein the method comprises the steps of:

1) culturing the progenitor cells to obtain a culture of exponential growing cells,

2) transfering an aliquot of the cells to fresh medium containing ethidium bromide (EtBr)₁

3) transfering the culture to one ore more containers to form a 0.5 - 10 mm thick layer of culture,

4) subjecting the culture to a UV treatment,

5) culturing the mutated cells to obtain a culture of exponential growing cells,

6) transfering an aliquot of bacteria to one or more petridishes containing a suitable agar growh medium, the aliquot of bacteria are selected to give single colonies,

7) identifying those colonies that have acquired antibiotic sensitivity by replica plating to petridishes with and without antibiotic, and

8) isolating, expanding and keeping those antibiotic sensitive colonies identified as a new antibiotica sensitive strain.

9. The method according to claim 8, wherein the culture subsequent to step 4) is subjected to an enrichment step for mutations comprising the steps of:

4a) transfering an aliquot of the UV treated culture to fresh medium containing a dose of a penicillin analogue which is detrimental to exponentially growing cells, but tolerable to non-growing cells, and

4b) culturing the cells in said penicillin analogue comprising medium under conditions, which would promote exponential growth in the absence of penicillin or an analogue of penicillin such as ampicillin. 10. The method according to any of the previous claims, wherein the culture is performed at a reduced oxygen tension.

11. The method according to any of the preceeding claims, wherein the UV-treatment of 5 step 4) reduces the number of living cells measured by Colony Forming Units (CFUs) to less that 20% relative to the number of the CFUs of the culture immediately before the UV-treatment.

12. The method according to any of claims 1-10, wherein the penicillin analogue is am- 10 phicillin being used at a dose of 50-300 microgramg/ml medium.

13. The method according to any of the preceeding claims, wherein tetracyclines is a antibioticum selected from the group of tetracycline, terramycin, demeclocycline, me- clocycline, doxycycline / doxycyclin, lymecycline, methacycline, minocycline, oxytetracy-

15 dine, rolitetracycline, aureomycin and other chlortetracyclines.

14. The method according to any of the preceeding claims, wherein the progenitor strain is selected from the group of Bifidobacteriacea comprising Bifidobacterium longum, Bifidobacterium pseudocatenulatum, Bifidobacterium bifidum, Bifidobacterium lactis, Bifi-

20 dobacterium animalis and subspecies thereof.

15. The method according to any of the preceeding claims, wherein the progenitor strain is a strain of Bifidobacterium animalis subspecies lactis.

25 16. The method according to any of the preceeding claims, wherein the Minimum inhibi- tive Concentration (MIC) of antibiotic of the progenitor strain is at least 10-fold higher than the MIC of the antibiotic sensitive strain.

17. The method according to any of the preceeding claims, wherein the Minimum inhibi- 30 tive Concentration (MIC) of tetracycline of the progenitor strain is at least 10 micro- gram/ml and the MIC of tetracycline of the antibiotic sensitive strain is 1 microgram/ml or less. 18. A strain of Bifidobacterium sp. containing a mutated, chromosomal Iy encoded tetW rendering the strain sensitive to tetracyclines obtainable by the method of any of the preceeding claims.

5 19. The Bifidobacterium strain according to claim 18, wherein tetracyclines is a antibiotic selected from the group of tetracycline, terramycin, demeclocycline, meclocycline, doxycycline / doxycyclin, lymecycline, methacycline, minocycline, oxytetracycline, rolitet- racycline, aureomycin and other chlortetracyclines.

10 20. The Bifidobacterium strain according to any of claims 18 or 19, wherein the progenitor strain is selected from the group of Bifidobacteriacea comprising Bifidobacterium longum, Bifidobacterium pseudocatenulatum, Bifidobacterium bifidum, Bifidobacterium lactis, Bifidobacterium animalis and subspecies thereof.

15 21. The Bifidobacterium strain according to any of claims 18 to 20, wherein the progenitor strain is a strain of Bifidobacterium animalis subspecies lactis.

22. The Bifidobacterium strain according to any of claims 18 to 21, wherein the progenitor strain is Bifidobacterium animalis subspecies lactis strain CHCC5445 (Bb-12®), de-

20 posited on September 30 , 2003 with the Deutsche Sammlung von Mikroorganismen und Zellkulturen under accession number DSM15954.

23. The Bifidobacterium strain according to any of claims 18 to 22, wherein the progenitor strain is Bifidobacterium animalis subspecies lactis strain CHCC7158, deposited on

25 April 28, 2005 with the Deutsche Sammlung von Mikroorganismen und Zellkulturen under accession number DSM 17280.

24. The Bifidobacterium strain according to any of claims 18 to 23, wherein the Minimum inhibitive Concentration of antibiotic (MIC) of the progenitor strain is at least 10-fold

30 higher than the MIC of the antibiotic sensitive strain.

25. The Bifidobacterium strain according to any of claims 18 to 23, wherein the Minimum inhibitive Concentration (MIC) of tetracycline of the progenitor strain is at least 10 micro- gram/ml and the MIC of the antibiotic sensitive strain is 1 microgram tetracycline /ml or

35 less. 26. The Bifidobacterium strain according to any of claims 18 to 23, characterized in that it is susceptible to a concentration of tetracyclines that is 1 ,0 μg/ml or less according to the E-test susceptibility screening assay.

5

27. The Bifidobacterium strain according any of claims 18 to 25, wherein the fefWgene comprises at least one sequence selected from the group of SEQ ID 3 [GGA TAC TGA ACC], SEQ ID NO: 6 [GTG GTT TAG TCT] and SEQ ID NO: 27 [AC CAG CGT TTT C].

10

28. The Bifidobacterium strain according to claim 27, wherein the fefWgene comprises SEQ ID 3 [GGA TAC TGA ACC].

29. The Bifidobacterium strain according to claim 27, wherein the fefWgene comprises 15 SEQ ID NO: 6 [GTG GTT TAG TCT].

30. The Bifidobacterium strain according to claim 27, wherein the fefWgene comprises SEQ ID NO: 27 [AC CAG CGT TTT C].

20 31. The Bifidobacterium strain according any of claims 18 to 25, wherein the fefWgene comprises the sequences SEQ ID NO: 28 [CG CCC TGC CAC A] and SEQ ID NO: 29 [AT ATT GTC ATC A].

32. The Bifidobacterium strain according any of claims 18 to 25, wherein the tetW gene 25 comprises the sequences SEQ ID NO: 30 [TA GAC GAT GGA A], SEQ ID NO: 31 [CG

GTC CGG GTA A] and SEQ ID NO: 32 [CT GAT CCG GCC TT].

33. The Bifidobacterium strain according to claim 18, which is identified as Bifidobacterium animalis subspecies lactis strain CHCC8902 (Bb-12Tet-S139) and deposited on

30 April 28, 2005 with the Deutsche Sammlung von Mikroorganismen und Zellkulturen under accession number DSM17281.

34. The Bifidobacterium strain according to claim 18, which is identified as Bifidobacterium animalis subspecies lactis strain CHCC9070 (DR10Tet-S9X) and deposited on April 28, 2005 with the Deutsche Sammlung von Mikroorganismen und Zellkulturen under accession number DSM 17282.

35. A Bifidobacterium strain which is sensitive to tetracyclines due to a mutation in tetW said Bifidobacterium strain is derived from a progenitor strain which is resistant to tetracyclines due to the presence of a tet W located on the chromosome.

36. The Bifidobacterium strain according to claim 35, wherein tetracyclines is a antibiotic selected from the group consisting of tetracycline, terramycin, demeclocycline, meclo- cycline, doxycycline/doxycyclin, lymecycline, methacycline, minocycline, oxytetracycline, rolitetracycline, aureomycin and other chlortetracyclines.

37. The Bifidobacterium strain according to any of claims 35 or 36, wherein the progenitor strain is selected from the group consisting of Bifidobacteriacea comprising Bifido- bacterium longum, Bifidobacterium pseudocatenulatum, Bifidobacterium bifidum, Bifidobacterium lactis, Bifidobacterium animalis and subspecies thereof.

38. The Bifidobacterium strain according to any of claims 35 to 37, wherein the progenitor strain is a strain of Bifidobacterium animalis subspecies lactis.

39. The Bifidobacterium strain according to any of claims 35 to 38, wherein the progenitor strain is Bifidobacterium animalis subspecies lactis strain CHCC5445 (Bb-12®), deposited on September 30 , 2003 with the Deutsche Sammlung von Mikroorganismen und Zellkulturen under accession number DSM15954.

40. The Bifidobacterium strain according to any of claims 35 to 39, wherein the progenitor strain is Bifidobacterium animalis subspecies lactis strain CHCC7158, deposited on April 28, 2005 with the Deutsche Sammlung von Mikroorganismen und Zellkulturen under accession number DSM 17280.

41. The Bifidobacterium strain according to any of claims 35 to 40, wherein the Minimum inhibitive Concentration of antibiotic (MIC) of the progenitor strain is at least 10-fold higher than the MIC of the antibiotic sensitive strain. 42. The Bifidobacterium strain according to any of claims 35 to 40, wherein the Minimum inhibitive Concentration (MIC) of tetracycline of the progenitor strain is at least 10 mi- crogram/ml and the MIC of the antibiotic sensitive strain is 1 microgram tetracycline /ml or less.

5

43. The Bifidobacterium strain according to any of claims 35 to 42 or claims 72 to 74, wherein the tetW gene comprises at least one sequence selected from the group of SEQ ID 3 [GGA TAC TGA ACC], SEQ ID NO: 6 [GTG GTT TAG TCT] and SEQ ID NO: 27 [AC CAG CGT TTT C].

10

44. The Bifidobacterium strain according any of claims 35 to 42 or claims 72 to 74, wherein the fefWgene comprises the sequences SEQ ID NO: 28 [CG CCC TGC CAC A] and SEQ ID NO: 29 [AT ATT GTC ATC A].

15 45. The Bifidobacterium strain according any of claims 35 to 42 or claims 72 to 74, wherein the tetW gene comprises the sequences SEQ ID NO: 30 [TA GAC GAT GGA A], SEQ ID NO: 31 [CG GTC CGG GTA A] and SEQ ID NO: 32 [CT GAT CCG GCC TT].

20 46. The Bifidobacterium strain according to claim 43, wherein the fefWgene comprises SEQ ID NO: 3 [GGA TAC TGA ACC].

47. The Bifidobacterium strain according to claim 43, wherein the fefWgene comprises SEQ ID NO: 6 [GTG GTT TAG TCT].

25

48. The Bifidobacterium strain according to claim 43, wherein the fefWgene comprises SEQ ID NO: 27 [AC CAG CGT TTT C].

49. The Bifidobacterium strain according to any of claims 35 to 46 or claims 72 to 74, 30 which is identified as Bifidobacterium animalis subspecies lactis strain CHCC8902 (Bb-

12Tet-S139) and deposited on April 28, 2005 with the Deutsche Sammlung von Mikro- organismen und Zellkulturen under accession number DSM 17281.

50. The Bifidobacterium strain according to any of claims 35 to 45, claim 47 or claims 72 35 to 74, which is identified as Bifidobacterium animalis subspecies lactis strain CHCC9070 (DR10Tet-S9X) and deposited on April 28, 2005 with the Deutsche Sammlung von Mik- roorganismen und Zellkulturen under accession number DSM 17282.

51. Use of a Bifidobacterium strain according to any of claims 18 to 50 for the prepara- 5 tion of an ingestible material or a bacterial culture.

52. The use according to claim 51 , wherein the bacterial culture is further processed.

53. The use according to claim 51, wherein the ingestible material is a fermentated food 10 or feed product.

54. The use according to claim 53, wherein the fermentated food or feed product is further processed.

15 55. The use according to claim 51 , wherein the ingestible material comprises Bifidobacteria in an amount from about 10⁵ cfu / g to about 10¹² cfu / g ingestible material.

56. The use according to any of the claims 51 to 55, wherein the ingestible material is a composition selected from the group consisting of milk, curd, milk based fermented

20 products, acidified milk, yoghurt, frozen yoghurt, milk powder, milk based powders, milk concentrate, cheese, cheese spreads, dressings, beverages, ice creams, fermented cereal based products, infant formulae and soybean milk.

57. The use according to any of the claims 51 to 56, wherein the ingestible material is 25 used for the preparation of a composition for the treatment and/or prevention of a disease, syndrome or condition, or for improving digestion of nutrients, or for improving the general health status of a human being or a vertebrate animal.

58. The use according to any of the claims 51 to 57, wherein the ingestible material is 30 used as a probiotic.

59. The use according to claims 51 or 58, wherein the ingestible material is a composition selected from the group consisting of milk, curd, milk based fermented products, acidified milk, yoghurt, frozen yoghurt, milk powder, milk based powders, milk concen-

35 trate, cheese, cheese spreads, dressings, beverages, ice creams, fermented cereal based products, infant formulae, tablets, capsules, liquid bacterial suspensions, dried oral supplement, wet oral supplement, dry tube feeding or wet tube feeding.

60. The use according to claim 51, wherein said disease, syndrome or condition is se- 5 lected from the group consisting of antibiotic-associated disorders, gastroenteritis, diarrhoea including traveller's diarrhoea and acute infantile diarrhoea, lactose intolerance, gastrointestinal infections and colonization of the gastrointestinal tract by pathogenic bacteria including Helicobacter pylori and Clostridium difficile, irritable bowel syndrome (IBS), inflammatory bowel disease (IBD), colonic cancer, urogenital infections and tu-

10 mours, vaginal infections, allergy (especially atopic eczema), vaccination, cho- lestrolemia and hypertension.

61. The use according to any of claims 57 to 60, wherein the ingestible material is suitable for preventing or treating infections with pathogens.

15

62. A food or feed product comprising the bacterial strain of any of claims 18 to 50.

63. The use of a Bifidobacterium strain according to any of claims 18 to 50 for the preparation of a starter culture.

20

64. Use according to claim 63, wherein the starter culture is frozen.

65. Use according to claim 63, wherein the starter culture is freeze dried.

25 66. Use according to claim 63, wherein the starter culture is spray/fluid bed dried.

67. A starter culture composition comprising the bacterium of any of claims 18 to 50, preferably wherein the starter culture composition has a concentration of viable cells, which is in the range of 10⁴ to 10¹² cfu per gram of the composition.

30

68. The starter culture composition according to claim 67, which in addition comprises one or more cryo protective agent(s) selected from the group consisting of inosine-5¹- monophosphate (IMP), adenosine-5'-monophosphate (AMP), guanosine-5¹- monophosphate (GMP), uranosine-5'-monophosphate (UMP), cytidine-5¹-

35 monophosphate (CMP), adenine, guanine, uracil, cytosine, adenosine, guanosine, uridine, cytidine, hypoxanthine, xanthine, hypoxanthine, orotidine, thymidine, inosine and a derivative of any of such compounds.

69. A method for making a frozen starter culture comprising the following steps: 5 1. culturing a bacterial strain according to claims 18 to 50

2. harvesting the propagated cells to provide a concentrated bacterial culture,

3. freezing the bacterial material to get frozen material, and

4. packing the freeze dried material in a suitable container.

10 70. A method for making a freeze dried starter culture comprising the following steps:

1. culturing a bacterial strain according to claims 18 to 50

2. harvesting the propagated cells to provide a concentrated bacterial culture,

3. freezing the bacterial material to get frozen material,

4. sublimation of water from the frozen material, and

15 5. packing the freeze dried material in a suitable container.

71. A method according to claims 69 or 70, wherein step 3 is performed by dripping the concentrated culture into liquid nitrogen and collecting the frozen material.

20 72. The Bifidobacterium strain according to any of claims 35 to 42, wherein the tetW gene comprises at least one sequence selected from the group of [ATACTGAA], [GGTTTAGT] and [CAGCGTTT].

73. The Bifidobacterium strain according any of claims 35 to 42, wherein the fefWgene 25 comprises the sequences [CCCTGCCA] and [ATTGTCAT].

74. The Bifidobacterium strain according any of claims 35 to 42, wherein the fefWgene comprises the sequences [GACGATGG], [GTCCGGGT] and [GATCCGGC].

30 The invention is illustrated in the following non-limiting examples and tables, wherein Table 1 is a description of oligonucleotides used for PCR analyses and DNA sequencing of the tetracycline resistance-encoding fefWgene of Bb-12® and HN019. Table 2 is the tetW DNA sequence and the upstream transposase gene, tps, from Bi- fido-bacterium animalis subsp. lactis Bb-12® (SEQ ID 22). The nucleotide sequence of

35 the TetW gene and flanking region from Bifidobacterium animalis subsp. lactis Bb-12®. The sequence was obtained by sequencing at Chr. Hansen A/S. Upstream is the trans- posase encoding open reading frame, nt. # 4 -966, with the amino acid depicted under the DNA sequence (M. W. approx. 35 kDa). The nt. sequence # 1318-3234 is the tetracycline resistant encoding gene, tetW , with the amino acid outlined under the DNA se- quence. (M. W. approx. 70 kDa).

The amber mutation at nucleotide (nt) position # 1741 (nt # 424 relative to the start codon of tetW) for the tetracycline sensitive strain, DR10Tet-S9X (CHCC9070), is indicated above the DNA sequence. The frameshift mutation at nt position # 2722 (nt #1405 relative to the start codon) for the tetracycline sensitive strain, Bb12Tet-S139 (CHCC8902), is indicated above the DNA sequence. *): indicates a stop codon.

Table 8-1 : List of reference strains used to verify the specific detection of Bb-12Tet- S139.

Table 9-1 : Conditions for stability testing of freeze-dried cultures.

Table 9-2: Survival of freeze-dried cultures (%).

Table 10-1. Survival in artificial gastric juice (%). Average of three experiments

Table 11-1. Tolerance to bile acids. Bacterial growh on MRS-Cystein HCI agar plates supplemented with 2 % w/v bile salts.

Table 12-1. Minimum inhibitory concentrations (MICs) of tetracycline of probiotic strains of Bifidobacterium animalis subspecies lactis and two derivatives thereof.

Table 13-1. Minimum inhibitory concentrations (MICs) of tetracycline Bb-12 and 3 new derivatives thereof.

EXAMPLES

Example 1 : Inactivation of the tefWgene in two probiotic strains of Bifidobacterium animalis subspecies lactis expressing resistance to tetracycline. A strong and dual mutagenic approach was used to inactivate the intrinsic tetracycline resistance of the genome of Bifidobacerium animalis ssp. lactis strain Bb-12® and strain HN019 (DR10™). This included treatment of the cells with the mutagen, ethidium bromide (EtBr) followed by ultra violet irradiation in a more forceful scale than normal when the mutagens are used individually.

Strains and culture conditions.

Strains of Bifidobacterium animalis subspecies lactis Bb-12® and HN019 (DR10™) were obtained from the culture collection of Chr. Hansen A/S, Hørsholm, Denmark. B. animalis subsp. lactis strain Bb-12® has the accession number CHCC5445 in the Hansen culture collection, and is deposited with the Deutsche Sammlung von Mikroorgan- ismen und Zellkulturen (DSMZ) under accession number DSM 15954. B. animalis subsp. lactis strain HN019 (DR10™) was isolated from a commercially available infant formula product labeled Femleaf DR-10 bifidus and sold in Taiwan during 2000. It has the ac- cession number CHCC7158 in the Hansen culture collection and is deposited with DSMZ under accession number DSM 17280.

The two strains that are resistant to tetracycline (at least 15 μg/ml, as determined by the E-test procedure, Danielsen and Wind, 2003), were grown routinely under anaerobically conditions at 37°C in Difco-MRS broth (deMan 1960), supplied with 0.05% Cysteine hydrochloride (Cysteine-HCI, Merck chemicals) as well as on MRS agar (1.5% agar) with the same concentration of Cysteine-HCI and 15 μg of tetracycline per ml.

Mutagenic treatment of Bb-12 An aliquot (2%) of a Bb-12® grown overnight (on) in MRS was transferred to fresh MRS broth (10 ml without tetracycline) containing 20μg/ml ethidium bromide (EtBr) and incubated to optical density [OD] at 600 nm, 0.35. The exponentially growing cells were then subjected to UV-irradiation (UV cross-linker, Stratagene) in an open Petri dish for 5 min (70 mJ/cm²).The UV treatment was repeated once after a dark interval of 5 min at room temperature. The treatment was adjusted to obtain a lethality of approximately 90%. The lethality was assessed as follows: The viability of the cells immediately after the EtBr-UV treatments was determined by cell plating on MRS agar without tetracycline and the lethality was calculated from the observed CFU. One ml of the mutagenised culture was then transferred to 9 ml fresh MRS without the addition of EtBr and was then allowed to grow for a period of 16 hours at 37°C in complete darkness, at which point aliquots of the treated cells were re-inoculated (1% [vol/vol]) into fresh MRS broth and allowed to grow for an additional 16 hours.

Example 2: Selection of tetracycline-sensitive variants of two probiotic strains of Bifidobacterium animalis subspecies lactis.

Screening procedure Screening for tetracycline sensitive isolates was performed after an ampicillin enrichment procedure (Miller, 1972) adapted to Bifidobacteriae was performed. Briefly, the ampicillin enrichment procedure was performed by transferring an aliquot (1 %) of the out-grown mutagenized culture to fresh MRS medium (10 ml) and growing the cells to an OD₆₀₀ of 0.2 without the addition of tetracycline. 0.5 ml of this culture was used to inoculate 10 ml of MRS broth containing 10 microgram tetracycline/ml and incubated for 2 hrs at 37°C at reduced oxygen tension, after which ampicillin was added to a final concentration of 150 microgram/ml, and the culture was continuously incubated for 16 hrs at 37°C. As ampicillin only kills growing cells (i. e., Tet^R cells) and not nondividing cells (i. e. mutant Tet^s cells), the addition of ampicillin can be considered an enrichment step for the subsequent isolation of Tet^s mutants. Cells were harvested by centrifugation (4,000 x G for 5 min at 4°C) and washed twice with fresh MRS broth.

Following the ampicillin enrichment, the screening for tetracycline sensitive isolates was performed by plating aliquots of the washed cells on MRS agar in an appropriate dilution to give approximately 150 colonies per plate after incubation at 37°C for 20 hours.

Tetracycline sensitive colonies were identified by replica plating on MRS agar without antibiotics and MRS agar containing 10 μg of tetracycline per ml, on which the tetracycline sensitive isolates were unable to grow. Finally, the tetracycline sensitive colonies were cultured in MRS broth. Total genomic DNA was isolated from both the tetracycline sensitive clones and the tetracycline resistant strain for intensive characterization. The replica screening resulted in 155 tetracycline sensitive isolates from CHCC5445 of a total of approximately 4,000 screened colonies. From CHCC7158, 43 tetracycline sensitive colonies were isolated out of approximately 1 ,000 cells. All these colonies were further tested in liquid MRS broth containing tetracycline (10 μg/ml). A substantial fraction of false positives (approx. 85 %) managed to grow under these conditions. The remaining tetracycline sensitive isolates were then subjected to E-test susceptibility screening to determine their tetracycline sensitive threshold.

The E-test was performed according to the method of the manufacturer (AB BIODISK, Sweden), slightly modified by M. Danielsen and A. Wind (2003), Briefly, determination of the Minimum Inhibitory Concentration (MIC) value for the individual isolates was performed by dipping a sterile cotton swab into an overnight culture of the tetracycline sensitive strain to be tested and to streak the entire surface of a MRS agar plate (diameter: 8,5 cm) evenly in three directions. After dryness of the applied inoculum, an E-test strip was applied to the agar surface by help of a manual applicator with the MIC scale facing upwards. Plates were inoculated anaerobically overnight in an inverted position at 37 ⁰C. The MIC value was determined by reading the value where the edge of the inhibition ellipse intersects the strip. In most cases it ranged between 2 and 4 μg/ml. Only two iso- lates, one derived from CHCC5445, named Bb12Tet-S139, and one derived from

CHCC7158, named DR10Tet-S9X, demonstrated a higher sensitivity to tetracycline with a MIC value of 0.5 μg/ml.

Example 3: Molecular characterization of the tetracycline-sensitive derivatives of two probiotic strains of Bifidobacterium animalis subspecies lactis.

PCR amplification and DNA sequencing of the fefWgene

Genomic DNA was prepared from wild type Bb-12® and the two tetracycline-sensitive isolates by the use of the Easy-DNA protocol for isolation of DNA from gram-positive bacteria according to the manufacturer's (Qiagen) instructions.

The fefWgene of the sensitive variants was characterized by PCR analyses according to the protocol of lnnis and Gelfand (1990) and DNA sequenced to test for possible mu- tations in that gene. The entire open reading frame (ORF, approx. 2.0 kb) of fefWwas amplified from each isolate in three overlapping fragments (A, B and C) with three sets of primers (table 1 , table 2).

Fragment A (approx. 785 bp) was amplified with sense primer: fefWx.DI, derived from a sequence 296 bp upstream of the start codon of the fefWgene and antisense primer: fefWx.R2, derived from the ORF of tetW. Fragment B (approx. 935 bp) was amplified with sense primer: tetWx.DΛ and antisense primer: tetWx.Rδ of the ORF of tetW. Fragment C (920 bp) was amplified with sense primer: 7efWx.D3 derived from the ORF and antisense primer: fe.Wx.R4 262 bp downstream of the termination codon of the tetW 5 gene.

The amplified fragments from the three PCR reactions were subjected to agarose gel- electrophoresis (0.7%) and staining in EtBr and identified with UV illumination. The bands corresponding to the three amplified gene fragments were excised from the gel

10 and DNA extracted (QIAquick gel extraction kit from Qiagen). The purified PCR products were cloned into the plasmid vector, pCR2.1-TOPO (Invitrogen), for nucleotide sequence determination using the M 13 forward and reverse primers. DNA sequencing of the tetW genes from each of the individual tetracycline sensitive isolates with E-test-values of 2-4 μg/ml demonstrated that the tetracycline resistance gene

15 was not affected or mutated in these isolates, and was 100% homologous to the tetW gene in the wild type Bb-12® depicted in Table 2.

Sequencing of the tetW genes from the two isolates with tetracycline E-test-values of 0.5 μg tetracycline/ml showed that in both cases the fefWgene was affected. The 20 Bb12Tet-S139 (a derivative of CHCC5445) demonstrated a frameshift at nucleotide position #2722, where a thymidine residue was deleted as illustrated below and in table 2.

Amino acid sequence: - Ser Leu GIy Tyr Leu Asn GIn Ser Bb-12® (CHCC5445) nt # 2710: - TCG CTG GGA TAC JJG AAC CAG AGT - 25

Bb12Tet-S139 (CHCC8902) nt # 2710: - TCG CTG GGA TAC TGA ACC AGA GTT - Amino acid sequence: - Ser Leu GIy Tyr opal (stop codon).

30 The illustration above shows a partial sequence of the fefWgene in CHCC5445. The underlined thymidine residue in Bb-12® (nt: 2722 in the tet W sequence) is deleted in the frameshift mutant, Bb12Tet-S139, resulting in an opal stop/nonsense codon 170 amino acids short of the wild type fefWgene product, [nt #2722 has the nt position number # 1405 in the sequence of tetW in table 2, SEQ ID

35 22]. DNA sequencing of the tetW gene from the other tetracycline sensitive isolate DRIOTet- S9X, a derivative of strain HN019 (CHCC7158), demonstrated a transition of a cytidine to a thymidine residue at nucleotide position # 174, thus immediately generating an am- ber translational stop codon as depicted below and in Tabel 2.

Amino acid sequence: - GIn Ser VaI VaI GIn Ser VaI Arg - DR10™ (HN019, CHCC7158) nt # 2729: -CAG AGC GTG GTT CAG TCT GTT CGG-

DR10Tet-S9X (CHCC9070) nt # 2729: -CAG AGC GTG GTT TAG TCT GTT CGG- Amino acid sequence: - GIn Ser VaI VaI amber (stop codon).

The illustration above shows a partial sequence of the fefWgene in CHCC7158, which is identical to the fefWgene in CHCC5445. The underlined cytidine residue in HN019 (nt: 1741) is substituted with a thymidine residue in the mutant strain, resulting in an amber stop/nonsense codon 498 amino acids short of the wild type fefWgene product, [nt # 1741 has the nt position number # 424 in DNA sequence of tetW in in table 2, SEQ ID 22].

Example 4: Genetic stability of the tetracycline sensitive isolates Bb12Tet-S139 (CHCC8902), DR10Tet-S9X(CHCC9070) and Bb12Tet-S180.

Determination of back mutation rates by cell plating on MRS agar with tetracycline One ml of a culture of the Bb12Tet-S139 mutant strain (1.6 x 10^~9 cells/ml) grown overnight was spread with 50 μl each onto 20 Petri dishes (diameter: 13.8 cm) with MRS agar supplied with tetracycline (15 μg/ml). After 24 hours of anaerobic incubation at 37°C, no colonies could be detected on the plates demonstrating that the reversion rate is less than 1.6 x 10⁹.

The same stability testing was performed for the DR10Tet-S9X strain. An over night culture of this strain (1.1 x 10^~9 cells/ml) was likewise spread with 50 μl each onto 20 Petri dishes with MRS agar supplied with tetracycline (15 μg/ml). After the incubation period, 19 tetracycline resistant colonies were detected. The reversion rate for the am- ber mutation was calculated to 1.8 x 10^~8. The reversion rate for the Bb12Tet-S180 strain was calculated to 1.7 x 10^~7.

Example 5: Physiological and phenotypic testings of the two tetracycline sensi- tive strains, Bb12Tet-S139 (CHCC8902) and DR10Tet-S9X(CHCC9070).

Growth conditions of the mutant strains in MRS broth.

Growth of the Bb12Tet-S139 and DR10Tet-S9X was compared (in triplicates) to their mother strains, CHCC5445 and CHCC7158, respectively, grown under similar condi- tions in MRS broth (200 ml with Cysteine-HCI) over a period of 24 hours. Samples for measuring the optical density at 600 nm was monitored all along the incubation period. The growth rates for both mutants were similar to those of the parent wild type strains indicating that the mutagenic treatment of the tetracycline sensitive isolates did not seem to hamper genes in their fermentative pathways.

Acidification rates of the two tetW mutants.

The acidification (MRS broth), i.e. the conversion of pyruvate to lactic acid, was monitored (in duplicates) over a period of 6 hours and compared to the respective mother strains grown under the same conditions. No obvious difference in the rate of acidifica- tion was observed between the mutant derivatives of CHCC5445 and CHCC7158 and their mother strains.

DNA-fingerprinting analysis.

Pulsed-field gel-electrophoresis of the genomic Spel- and Xbal-digested DNA from the two mutant tetW strains was performed according to standard methods (Hung and Bandziulis, 1990), and did not reveal any rearrangement of the Spel- orXbal-digested chromosomal pattern when compared to the respective wild type strains. This adds evidence to an overall isogenic background of the mutants and the mother strains.

Example 6: Genome wide gene expression (transcriptomic) analysis shows that the gene-expression of Bb12Tet-S139 is indistinguishable from Bb-12®.

Materials & Methods

Design and production of whole genome microarrays for Bb12 We have previously sequenced and set up whole genome microarrays for Bb12® (Gar- rigues et al. 2005). Briefly, Bb-12® was shotgun sequenced, resulting in 56 contigs. Through further assembly analysis, it was clear that only a couple of percent of the sequence was missing. Within the almost 2.0 Mb genome sequence, 1612 putative CDSs (coding sequences) were identified. A specific 65-75mer oligo was designed for each gene with a few exceptions, such as very small putative genes. For a couple of genes, several oligos were designed. In all, 1569 oligos were designed from the sequence. In addition more than 100 control oligos were designed. Oligos were printed on UltraGAPS slides (Corning B. V., Schiphol-Rijk, The Netherlands) in four replicate copies as de- scribed previously (Pedersen et al. 2005).

RNA samples were collected in RNAprotect (QIAGEN, Valencia, CA, USA) to stabilize the expression profile and total RNA was isolated (RNeasy, QIAGEN). 10 μg of RNA was copied into cDNA using the CyScribe Post-Labelling Kit with 1.65 μg of random nonamer as primer (Amersham Biosciences, Hillerød, Denmark). The test condition was labeled with Cy5 and the reference condition with Cy3. The two samples were pooled, and half of this was hybridized to the array. Instead of the 50% formamide recommended in the protocol, 60% was used (these conditions were established previously using the control oligos). After around 18h of hybridization, the array was washed (Corn- ing B.V.), scanned, and pre-analyzed as described previously (Pedersen et al. 2005). The array data was imported into Acuity 4.0 (Axon Instruments Inc., Union City, CA, USA) where it was LOWESS normalized. A dataset was created with all identified spots. Data from oligos where only 0, 1 , or 2 of the 4 replicate spots had been identified were removed. Similarly, data from oligos where the standard deviation between the normal- ized Iog2(ratio)s was >0.5 were removed.

Results

The gene expression of Bb12Tet-139S was compared to that of Bb12 using the whole genome microarrays. Stationary cultures of both strains were inoculated at 1% (OD600=0.06) into fresh MRS+0.05% cysteine • HCI preheated at 37⁰C. OD600 was then measured every 30min. In the OD range of 0.1-1.0AU (absorbing units), growth was exponential. The specific growth rate, μ, was 0.5Oh^"1 (R2=0.9977) and 0.51 h^"1 (R2=0.9953) for Bb-12® and Bb12Tet-S139, respectively. Hence, there is no significant difference between the growth rates of the two strains. From RNA samples at OD=1.0AU (after six and half hours of growth) microarrays were produced. Bb12Tet- S139 and Bb-12® were the test and reference conditions, respectively. Of the 1569 genes represented on the microarray significant regulatory, data was obtained from 1271 genes.

As a rule of thumb, a gene is often considered to be differentially expressed if it is >2- fold up or down-regulated between two conditions (see for example Pedersen et al. 2005). None of the 1271 genes in the dataset were more than >2-fold differentially expressed. In comparison, when Bb12 was exposed to 0.1% bile salt, 86 and 123 genes were >2-fold up and down-regulated, respectively (Garrigues et al. 2005). Among these genes, 17 and 27 were even >4-fold up and down-regulated, respectively. This shows that if cell metabolism is perturbed, dramatic changes may occur with regards to gene expression. Similarly, when 1% of fructooligosaccharide (FOS) was added to the medium, only 2 genes were >2-fold differentially expressed. These 2 genes encode proteins involved in FOS utilization and were 5-fold up-regulated (Garrigues et al. 2005). This latter experiment shows that the growth conditions can be reproduced and that perturbations affecting particular parts of the metabolism can be identified. By combing the above results, it is clear that with regards to gene expression and general physiological state no adverse effects are observed in Bb12Tet-S139 compared to Bb-12®. Based on this, it can be assumed that Bb12Tet-S139 behaves as Bb-12® except for the sensitivity to tetracycline.

Example 7: Quantitative mutant specific detection of Bb-12Tet-S139.

In order to obtain a method for quantitative detection of BB-12TET-S139, a real-time PCR assay with a dual labeled probe was designed. The target for the assay is the tetW gene, more specifically the deletion site is targeted by the dual labeled probe.

Primers and probe

The primers were designed with the help of the publicly available program "Primer 3" (http://frodo.wi. mit.edu/cgi-bin/primer3/primer3_www.cgi) . The probe was designed manually. LNA (locked nucleic acid, a proprietory technology owned by Exiqon, Ved- baek, Denmark) derivatives were incorporated into the probe in order to be able to shorten the probe and thereby obtain higher specificity. The annealing temperature, secondary structure and primer/probe hybridization were assessed with the help of Exiqon's programs (http://lnatools.com). Primers were obtained from TAGC, Copenhagen, DK, the dual labeled probe was obtained from Exiqon, Vedbaek, DK.

Real time PCR reaction The PCR reaction was run on the ABI 7500 (Applied Biosystems) under standard conditions: 15 s denaturation at 95⁰C, 1 min annealing and elongation at 6O⁰C for 40 cycles. The following reagents were used: TaqMan® Universal PCR Master Mix (2x concentrated), 300 nM forward primer and backward primer, 200 nM probe. The reaction volume was 25 μl.

Results

Assay design

The assay design resulted in the following primers and probe: forward primer 5'- CAA TAC AAG AGC CGG GTT TC, backward primer 5'- GTG CTG ACC GGA CTG TAA TAA A -3', probe 5'-FAM-AtActgaaccA-TAMRA-3' (FAM = Carboxy-Fluorescein; TAMRA = Carboxy-Tetramethyl-rhodamin). Small letters in the probe sequence indicate LNA-derivatives. The size of the amplification product is 160 bp.

DNA extraction

DNA was extracted from pure cultures with the help of the DNeasy Tissue Kit (Qiagen, Germany) following the instructions of the manufacturer for extraction from gram positive bacteria. DNA was extracted from fecal samples with the help of the QIAamp Stool DNA extraction Kit Qiagen, Germany) following the instructions for pathogen detection as described by the manufacturer.

Specificity testing

The specificity of the assay was tested against the wild type, some Bifidobacterium reference strains (see table 8-1) and mouse and human fecal DNA.

The assay was fully specific for BB-12TET-S139, and no amplification above the threshold was observed for the wildtype or any of the other Bifidobacterium samples.

Conclusion

Thus, this assay can be used to identify Bifidobacterium animalis ssp. lactis strain BB- 12TET-S139.

Example 8: Production and stability of freeze-dried cultures

An examination of the formulated, freezedryed strains' ability to survive at 30°C for 3 weeks at 2 different oxygen and humidity levels was performed.

Materials:

Bb-12® (DSM 15954); 2 freeze-dried bulks and one blend Bb-12Tet-S139 (DSM 17281). 2 freezedried bulks and one blend. In total 6 samples are used for the study. The freeze- dried bulks are produced according to standard recipe. Blends are grinded, freeze-dried bulk mixed with dextrose with a water activity below 0.15.

Methods:

Each sample is divided into 3 portions, which are treated as indicated in table 9-1 for 3 weeks.

Table 9-1 : Conditions for stability testing of freeze-dried cultures.

After the test period, a CFU/g analysis is performed twice on all samples.

CFU/q

A known amount of sample is homogenized with diluent, and decimal dilutions are prepared. Appropriate dilutions are mixed with MRS Agar from OXOID added 0,05 % cys- tein-hydrochloride, then incubated for 3 days at 37°C in an anaerobic chamber using AnaerGen™ from OXOID. At least 4 petridishes with 30 to 300 colonies are used for the enumaration.

Survival:

The survival is calculated as follows:

Survival % : (Log CFU/g in sample after treatment *100)/( Log CFU/g in reference sample). Results:

Are shown in table 9-2 below.

Table 9-2: Survival of freeze-dryed cultures (%)

Conclusion:

There is no difference between Bb-12® and Bb-12Tet-S139 regarding their survival for 3 weeks at +30°C or their survival in sealed alu-bags at +30°C and approx. 15%rH. This is true both for pure freeze-dried cultures as well as for cultures mixed with exipients (blends).

Example 9: Survival in artificial gastric juice

The survival of a probiotic bacterium through the human gastrointestinal tract is consid- ered to be an important factor for its probiotic functionality.

Bifidobacterium animalis subsp. lactis strain Bb-12® has an excellent tolerance to gastric juice and bile salt. The in vitro test used for acid tolerance is based on the measurement of surviving bacteria after their exposure an artificial gastric juice.

Bifidobacterium animalis subsp. lactis Bb-12Tet-S139, cultured under anaerobic conditions overnight in MRS (Difco) at 37 ⁰C, was tested for its tolerance to the artificial gastric juice compared to BB-12. The gastric juice was made by mixing 2.0 g of sodium chloride (Merck 1.06404.1000) and 3.2 g and pepsin powder (Sigma P-7000) in water. Then 80 ml of 1 M hydrochloric acid was added and the mixture diluted to 1000 ml with H₂O. Final adjustment to pH=2 was done with 5 M NaOH. The overnight bacterial culture was washed three times with 0.9 % saline diluent supplemented with 1.5% tryptone at pH=7, and then added to the gastric juice followed by sampling at different time intervals.

The survival rate of the cells from each sample was assayed by plating the cells on MRS agar supplemented with 0.05% Cystein HCI and determining the number of colony forming units (c.f.u). The cells were exposed to the gastric juice (pH=2) at 37°C up to 90 min. The dataset (see table 10-1) was analysed by the Mann-Whitney U-test.

Conclusion

No significant difference was found between BB-12® and Bb-12Tet-S139 in relation to gastric acid tolerance.

Example 10: Tolerance to bile acids.

The survival of any potential probiotic bacterium through the human gastrointestinal tract is considered to be important for its probiotic functionality. Bifidobacterium animalis subsp. lactis strain Bb-12® has an excellent resistance to bile salt.

In the present experiment, the Bifidobacterium animalis subsp. lactis strain Bb-12Tet- S 139 was tested for its resistance to bovine and porcine bile extracts compared to Bb- 12®. Tolerance towards bile was assayed by plating cells on agar plates supplemented with bile salt of varying concentrations essentially as described by Noriega L. et. al. Int. J. Food Microbiol 94, 79-86, 2004. Minimum inhibitory concentration (MIC) determinations of both strains were made on MRS-Cystein HCI agar plates supplemented with two-fold serial dilutions of bovine bile (Sigma B3883) and porcine bile extract (Sigma B8631) in concentrations from 2% to 0,062% w/v.

Results

Both strains were shown to be tolerant to bile salt concentrations up to at least 2% .

Experiments were carried out in triplicate. Results are shown in table 11-1.

Table 11-1. Tolerance to bile acids. Bacterial growth on MRS-Cystein HCI agar plates supplemented with 2 % w/v bile salts.

+ indicates clear bacterial growth on all agar plates

Conclusion

Both Bb-12® and Bb-12Tet-S139 are tolerant to at least 2% bile acids, indicating a minimum inhibitory concentration that is higher than 2% for both strains. Tolerance to bile salts is indicative of adaptation to the conditions in the gastrointestinal tract.

Example 11: Three new tetracycline-sensitive derivatives of two probiotic strains of Bifidobacterium animalis subspecies lactis- their isolation and molecular characterization.

The three new derivatives were cultured, mutated, selected and characterized as described in Example 1 ,2 and 3. Bb-12Tet-S79 and Bb-12Tet-S180 are derivatives of Bifidobacterium animalis subspecies lactis Bb-12®. DR10Tet-S33 is a derivative of HN019 (DR10™).

Bb-12Tet-S180, DNA sequencing of the tetWgene from the tetracycline sensitive isolate Bb-12Tet-S180, a derivative of Bifidobacterium animalis subspecies lactis Bb-12® (CHCC5445), demonstrated a transversion of an adenine to a cytidine residue at nucletotide position # 2731 in Tab. 2 (SEQ ID 22) generating an amino acid substitution from a Serine to an Argin- ine as depicted below.

Amino acid sequence: - Tyr Leu Asn GIn Ser Phe GIn Asn Bb-12 (CHCC5445) nt # 2719 - TAC TTG AAC CAG AGT TTT CAA AAC

Bb-12Tet-S180 nt #2719 - TAC TTG AAC CAG CGT TTT CAA AAC Amino acid sequence: Tyr Leu Asn GIn Arg Phe GIn Asn

The above sequence show a partial amino acid sequence of the fefWgene found in CHCC5445. The underlined adenine residue in CHCC5445 (nt: 2731) is substituted with a cytidine residue in the mutant strain, resulting in an amino acid substitution 168 amino acids before the translational stop codon.

Multiple mutants DR10tet-S33 and Bb-12Tet-S79,

DNA sequencing of the tetW genes from the tetracycline sensitive isolates DRIOTet- S33 and Bb-12Tet-S79 demonstrated two and three nucleotide substitutions, respec- tively, each of which gave rise to an amino acid substitution in the fefWgene product as described below.

DR10tet-S33, nt # 1546[G] to 1546[T] in the triplet GGC to TGC resulted in an amino acid substitution of Glycine to Cysteine. nt # 1774[A] to 1774[G] in the triplet ATC to GTC resulted in an amino acid substitution of lsoleucine to Valine. See Tab. 2 (SEQ ID 22).

Bb-12Tet-S79, nt # 1358[C] to 1358[A] in the triplet GCT to GAT resulted in an amino acid substitution of Alanine to Aspartic acid. nt # 3023[A] to 3023[G] in the triplet CAG to CGG resulted in an amino acid substitution of Glutamine to Arginine. nt # 3095[T] to 3095[C] in the triplet CTG to CCG resulted in an amino acid substitution of Leucine to Proline. See Tab. 2 (SEQ ID 22).

Sensitivity,

The tet-sensitive isolates were subjected to E-test susceptibility screening according to the methods described by M. Danielsen and A. Wind (2003), to determine their tetracycline sensitive threshold. The result is summarized in table 12-1 below:

Example 12: Classification of tetracycline-sensitive variants of two probiotic strains of Bifidobacterium animalis subspecies lactis.

As mentioned in Example 2, approximately 85 % of the putitative "tetracycline sensitive" isolates managed to grow in liquid MRS broth containing tetracycline (10 μg/ml) under these conditions. The remaining 15% tetracycline sensitive isolates were then subjected to E-test susceptibility screening according to the methods described by M. Danielsen and A. Wind (2003), to determine their tetracycline sensitive threshold.

In general, the E-test revealed two classes of tetracycline sensitive mutants:

Class 1 : Growth at tetracycline cone, of 1 ,5 μg/ml or less according to the E-test; and Class 2: Growth at tetracycline concentrations > 1 ,5 μg/ml;

The tetWgene was analysed in a representative number of Class 1 and Class 2 tetra- cycline sensitive mutants.

The result being:

Class 1 : Growth at tetracycline cone. < 1 ,5 μg/ml; are tetracycline sensitive mutants that are characterized in having nucleotide (nt) deletions or nt substitutions, some of which resulting in the introduction of stop codons in the open reading frame of the fefWgene, and

Class 2: Growth at tetracycline concentrations > 1,5 μg/ml; no mutations in tetW. This class of mutations is most probably caused by mutations in cell walls or transport pro- teins.

Conclusion

Until now, all mutations that are characterized by an E-test value < 1 ,5 μg tet/ml contained a mutated tetW. This opens for a selection procedure, which results in the selec- tion of tetracycline-sensitive Bifidobacteria which, with a high probability, contains an inactivated fefWgene.

Example 13: Three additional tetracycline-sensitive derivatives of a probiotic strain of Bifidobacterium animalis subspecies lactis- their isolation and molecu- lar characterization.

The three new derivatives were cultured, mutated, selected and characterized as described in Example 1 , 2 and 3. Bb-12tetW-S73, Bb-12tetW-S14 and Bb-12tetW-S4 are derivatives of Bifidobacterium animalis subspecies lactis Bb-12®.

Bb-12tetW-S73, DNA sequencing of the tetW gene from the tetracycline sensitive isolate Bb-12tetW- S73, a derivative of Bifidobacterium animalis subspecies lactis Bb-12® (CHCC5445), demonstrated a change of a thymine to a guanine residue at nucletotide position # 1573 in Tab. 2 (SEQ ID 22) (TAC > GAC) generating an amino acid substitution from a Tyrosine to an Aspatic Acid.

Bb-12tetW-S14,

DNA sequencing of the tetW gene from the tetracycline sensitive isolate Bb-12tetW- S14, a derivative of Bifidobacterium animalis subspecies lactis Bb-12® (CHCC5445), demonstrated a change of a thymine to a cytosine residue at nucletotide position # 2869 in Tab. 2 (SEQ ID 22) (TCA > CCA) generating an amino acid substitution from a Serine to an Proline.

Bb-12tetW-S4,

DNA sequencing of the tetW gene from the tetracycline sensitive isolate Bb-12tetW-S4, a derivative of Bifidobacterium animalis subspecies lactis Bb-12® (CHCC5445), demonstrated a change of an adenine to a guanine residue at nucletotide position # 3176 in Tab. 2 (SEQ ID 22) (CAG > CGG) generating an amino acid substitution from a Gluta- mine to an Arginine.

Sensitivity,

The tet-sensitive isolates were subjected to E-test susceptibility screening according to the methods described by M. Danielsen and A. Wind (2003), to determine their tetracycline sensitive threshold. The result is summarized in table 13-1 below:

REFERENCES

Barbosa, T. M., K. P. Scott, and H. J. Flint. 1999. Evidence for recent intergeneric trans-fer of a new tetracycline resistance gene, tet(W), isolated from Butyrivibrio fibrisol- vens, and the occurrence of tet(O) in ruminal bacteria. Environ. Microbiol. 1 :53-64.

Billington, S. J, J. G. Songer, and B. H. Jost (2002) Widespread Distribution of a Tet W Determinant among Tetracycline-Resistant Isolates of the Animal Pathogen Arcanobac- terium pyogenes. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 46: 1281-1287.

Cai et al (2000) MicrobioL ImmunoL 44, 815-820

Chopra, I., and M. Roberts (2001). Tetracycline antibiotics: mode of action applications, molecular biology, and epidemiology of bacterial resistance". Microbiol. MoI. Biol. Rev. 65:232-260.

Chopra, I., and M. Roberts. 2001. Tetracycline antibiotics: mode of action, applications, molecular biology, and epidemiology of bacterial resistance. Microbiol. MoI. Biol. Rev. 65:232-260.

de Man, J. C, M. Rogosa, and M. E. Sharpe. 1960. A medium for the cultivation of lac- tobacilli. J. Appl. Bacteriol. 23:130-135.

EFSA (2005) Opinion of the Scientific Panel on Additives and Products or Substances used in Animal Feed on the updating of the criteria used in the assessment of bacteria for resistance to antibiotics of human or veterinary importance (Question N° EFSA-Q- 2004-079) The EFSA Journal 223, 1-12 . (http://www.efsa.eu.int/science/feedap/feedap opinions/993 en.html)

Garrigues, C, B. Stuer-Lauridsen and E. Johansen (2005). Characterisation of Bifidobacterium animalis subsp. lactis BB-12 and other probiotic bacteria using genomics, transcriptomics and proteomics. Aust. J. Dairy Tech. 60: 84-92.. Hung, L. and R. Bandziulis, Promega Notes 24: 1-2, 1990, Promega, Madison, Wis. Lachman, L. et al (Ed.) 1986. The Theory and Practice of Industrial Pharmacy. Third Edition. Lea & Febiger, Philadelphia.

List no. 62 (1997) Int. J. Syst. Bacteriol 47, 915-916

M. A. lnnis and D. H. Gelfand (1990) Optimization of PCRs, p. 3-12. In M. A. Innis, D. H. Gelfand, J. J. Sninsky, and T. J. White (ed), PCR protocols, a guide to methods and ap- plications. Academic Press, San Diego, Calif.

M. Danielsen and A. Wind. 2003 "Susceptibility of Lactobacillus spp. to antimicrobial agents". Int. J. Food Microbiol. 82:1-11.

Masco et al (2004) Int. J. Syst. EvoL MicrobiaL 54, 1137-1143

Meile et al (1997) System. AppL MicrobioL 20, 57-64

Miller, J. H. (1972) "Experiments in molecular genetics", p 230-234. Cold Spring Harbor Laboratory, Cold Spring Harbor, N. Y.

Minutes (2001) Int. J. Syst. EvoL MicrobioL 51 , 259-261

Moubareck, C. et al. (2005) Antimicorbial susceptibility of Bifidobacteria. J. Antimicrobial Chemotherapy 55: 38-44.

Pedersen, M. B., Iversen, S. L., Sørensen, K. I., and E. Johansen. 2005. The long and winding road from the research laboratory to industrial applications of lactic acid bacteria. FEMS Microbiology Reviews, accepted.

Scott, K.P., C. M. Melville, T. M. Barbosa, and H. J. Flint (2000) Occurrence of the New Tetracycline Resistance Gene tet(W) in Bacteria from the Human Gut. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 44: 775-777. Silliker, J. H. et al (Ed.) 1980. pH and acidity. IN: Microbial Ecology of Foods, vol. 1 pp. 92-111. Academic Press, New York.

Silva, A.M., Bambirra, E.A., Oliveira, A.L., Souza, P.P., Gomes, D.A., Vieira, E. C, 5 Nicoli, J. R. (1999) Protective effect of bifidus milk on the experimental infection with Salmonella enteritidis subsp. typhimurium in conventional and gnotobiotic mice. Journal of Applied Microbiology, 86: 331-336.

WO 97/16198, (Chr. Hansen A/S Biosystems), 9 May 1997 10

Yazid, A.M., A.M. AIi, M. Shuhaimi, V. Kalaivaani, M.Y. Rokiah and A. Reezal (2000) An-timicrobial susceptibility of bifidobacteria. Letters in Applied Microbiology 2000, 31, 57-62

15 Zhou, J. S., CJ. PillidgeC, P. K. Gopal and H. S. Gill (2005) Antibiotic susceptibility profiles of new probiotic Lactobacillus and Bifidobacterium strains. International Journal of Food Microbiology 98:211-217.

Regarding Deposited Microbial Organisms [EXPERT SOLUTION]

20

For all deposited microbial organisms mentioned in the present patent application the following applies.

In respect to those designations in which a European Patent is sought a sample of the 25 deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample, and approved either i) by the Applicant and/or ii) by the European Patent Office, whichever applies. (Rule 28 (4) and 30 28 (5) EPC).

INDICATIONS RELATING TO DEPOSITED MICROORGANISM OR OTHER BIOLOGICAL MATERIAL

(PCT Rule 136M)

A or other biological material referred to in the description

B IDENTIFICATION OFDEPOSJT Further deposits are identified on an additional sheet j [

Name of depositary institution DSMZ-Deutche Sammlung vor Mikroorganismen und Zellkulturen GmbH

Address of depositary institution (including postal code and country)

Mascheroder Weg 1 b D-38124 Brausnweig Germany

Date of deposit Accession Number

17 May 2005 DSM 17280

C ADDITIONAL INDICATIONS

blank if no! applicable) This information is continued on an additional sheet

D DESIGNATED STATFS FOR WHICH INDICATIONS ARE MAVZ (lfthe indications me not for all designated States)

E SEPARATE FURNISHING OF INDICATIONS Heme blank ifnol applicable)

The indications listed belov. will be submitted \o the International Buieau iater (specfiy the genei a) nature of the indications e e 'Accession \umbei of Deposit )

INDICATIONS RELATING TO DEPOSITED MICROORGANISMS

(PCT Rule 12bis)

Additional sheet

In addition to the microorganism indicated on page 16 of the description, the following microorganisms have been deposited with DSM-Deutsche Sammlung von Mikroorganismen und Cellkulturen GmbH

Mascheroder Weg 1b, D-38124 Braunschweig, Germany on the dates and under the accession numbers as stated below:

Accession Date of Description Description number deposit Page No. Line No.

DSM 17281 17 May 2005 22 32

DSM 17282 17 May 2005 23 13

DSM 15954 13 Oct. 2003 30 20

For all of the above-identified deposited microorganisms, the following additional indications apply:

As regards the respective Patent Offices of the respective designated states, the applicants request that a sample of the deposited microorganisms stated above only be made available to an expert nominated by the requester until the date on which the patent is granted or the date on which the application has been refused or withdrawn or is deemed to be withdrawn.

Table 1

Oligonucleotides used for PCR analyses and DNA sequencing of the tetracycline resistance-encoding tetW gene of Bb-12.

Primer Sequence (5' to 3') Nucleotide positions*

Stps.D5 GAGCATCGCTTAATTCCTTCGAGGGG -394 -369

StetW.D CGAGGGGACTTTGGCCCACCGCTGGGTGG -375 -347

StetW.Dl GCAGGCAGGCACGTCCATCCGCCTC -199 -175

Stps.R3 GGCTTCTGCCACCGTGGCCTCGTCAC 234 . 209 tpsW.Rl CCTGTCCTTGTCCACGCCGATATGCGC 554 526 tetWx.Dl CGGCACCTGCTGTATAATGCGGATTGTGGC 1022 1051 tetW.Dup GTGGGAACAAAGGATTATGATAGTCCC 1092 ^• 1118 tetWx.D4 GGCTGGCGTTGATTTGCAGAGCGTGG 1713 1738 tetW.D500 GCAGACGGTGTCGCTGTCCCCGG 1782 1804 tetWx.R2 CCGGGGACAGCGACACCGTCTGC 1804 : 1782 tetWx.D3 GGAGCGGCCGCTCAAAGCAGCCAGCC 2580 2625 tetWx.R3 GGCTGGCTGCTTTGAGCGGCCGCTCC 2625 : 2580 tetWx.R5 GCCCAAAACGGGTTGGGCGGCACCTCG 2645 2619 tetW.R500 CCAGCCCGTAACGGATACCATCCC 2773 2750 tetWx.R4 GATGGTCGCATGATCGGCGGGGTCACTCCC +262 +233

^*Numbering is based on the DNA sequence illustrated in table 2. The prefix "D" indi- cates a direct primer derived from the sense strand. The prefix "R" indicates a reverse primer complementary to the sense strand.

Table 2

The tetW DNA sequence flanked by the upstream transposase gene, tps, from Bifidobacterium animalis Bb-12 (SEQ ID 22).

1 ORF encoding a Transposase

CAGATGACGATTTCCGCATTCAGCGACGAACTGGCACAGGTGCGGACGAAGAAAAAAGCA 60 GTCTACTGCTAAAGGCGTAAGTCGCTGCTTGACCGTGTCCACGCCTGCTTCTTTTTTCGT M T I L A F S D E L A Q V R T K K K A

TTTCTCGACCAGATTGAACGGATCGTCCCGTGGAAGGAATGGCTTGCCATGATTCAGCCG ₁₂o AAAGAGCTGGTCTAACTTGCCTAGCAGGGCACCTTCCTTACCGAACGGTACTAAGTCGGC F L D Q I E R I V P W K E W L A M I Q P

TGCTATTACAAAGGAGAGCGCGGCAACAAACCCTATCCGCTGGAGATCATGCTCCGACTG _: , _: — — , _: — , _{: :} , — — — iiooun ACGATAATGTTTCCTCTCGCGCCGTTGTTTGGGATAGGCGACCTCTAGTACGAGGCTGAC C Y Y K G E R G N K P Y P L E I M L R L

TATCTGCTGCAAAΆCCTCTATGACCTGAGTGACGAGGCCACGGTGGCAGAAGCCATCGAC 240 ATAGACGACGTTTTGGAGATACTGGACTCACTGCTCCGGTGCCACCGTCTTCGGTAGCTG Y L L Q N L Y D L S D E A T V A E A I D

AGCCGCGCATTTTCGGAGTTCTGCGGCGTCGATTCCAGCAACCAGGTTCCGAACGGGGAT

_{: :} — „_— __: , —__: _, ——___: —_: JqπUnU TCGGCGCGTAAAAGCCTCAAGACGCCGCAGCTAAGGTCGTTGGTCCAAGGCTTGCCCCTA S R A F S E F C G V D S S N Q V P N G D

ACTCTTGGCCGGTTCCGGAACTTGCTGATCAAGAACGGACTGCAGGAGAAGCTGTTCGCT 360 TGAGAACCGGCCAAGGCCTTGAACGACTAGTTCTTGCCTGACGTCCTCTTCGACAAGCGA T L G R F R N L L I K N G L Q E K L F A

CAGGTGGTAGCAGCGCTCATGGAACGTGGCCTCATTCTGAAAAAGGGCACCATTGTAGAT _{: i : :} „ _/ion GTCCACCATCGTCGCGAGTACCTTGCACCGGAGTAAGACTTTTTCCCGTGGTAACATCTA Q V V A A L M E R G L I L K K G T I V D

TCCACCATCATTTCCGCCCCCTCTTCTACCAAGAATAAGGAAAAGAΆACGGGATCCGGAT

_: _ _ _/ion AGGTGGTAGTAAAGGCGGGGGAGAAGATGGTTCTTATTCCTTTTCTTTGCCCTAGGCCTA S T I I S A P S S T K N K E K K R D P D

GCCCACCAAGTCAAGAAGGGCAACACCTGGCACTTTGGGTACAAAGCGCATATCGGCGTG _{: : :} __: , c, _/in CGGGTGGTTCAGTTCTTCCCGTTGTGGACCGTGAAACCCATGTTTCGCGTATAGCCGCAC A H Q V K K G N T W H F G Y K A H I G V GACAAGGACAGCGGACTGGTTCACACAGTGGAAGCTACACCGGCAAATGTCCACGACGTT _„ „ __, , c^πc_\

CTGTTCCTGTCGCCTGACCAAGTGTGTCACCTTCGATGTGGCCGTTTACAGGTGCTGCAA D K D S G L V H T V E A T P A N V H D V

GCGGAAGTGCCGAAATTATTGACGGGAGAGGAAGAAACAGTCTATGGAGACAGCGGTTAT

CGCCTTCACGGCTTTAATAACTGCCCTCTCCTTCTTTGTCAGATACCTCTGTCGCCAATA A E V P K L L T G E E E T V Y G D S G Y

CTCGGCGCAGGTAAGCGCGAAGATGCCGTAGTCCGAAACAAAGCTGGCCGGAAAATCAAG 720

GAGCCGCGTCCATTCGCGCTTCTACGGCATCAGGCTTTGTTTCGACCGGCCTTTTAGTTC L G A G K R E D A V V R N K A G R K I K TACAAGATCAATCGTCGTCCATCGCAGATGAAGAΆACTGAGCAAAAGCGGGCAGTACGCA 7₈₀

ATGTTCTAGTTAGCAGCAGGTAGCGTCTACTTCTTTGACTCGTTTTCGCCCGTCATGCGT Y K I N R R P S Q M K K L S K S G Q Y A

GCAAAGAAAGCGGAACGGGCGAAATCCTCAGTGCGAGCAAAAGTAGAGCATGTATTCGGT

CGTTTCTTTCGCCTTGCCCGCTTTAGGAGTCACGCTCGTTTTCATCTCGTACATAAGCCA A K K A E R A K S S V R A K V E H V F G

GTCGTTAAGAAGCAGCTGCGCTTCCGAAAAACGCGATACCGAGGGCTTGAAAAGCAACAA 9₉₀

CAGCAATTCTTCGTCGACGCGAAGGCTTTTTGCGCTATGGCTCCCGAACTTTTCGTTGTT V V K K Q L R F R K T R Y R G L E K Q Q

GCCAAATTCAATATCATGTTTGCGTTGGCAAΆTCTGATTCTGGCTGACAGACCCTGTCTG __: ____: Q CO

CGGTTTAAGTTATAGTACAAACGCAACCGTTTAGACTAAGACCGACTGTCTGGGACAGAC A K F N I M F A L A N L I L A D R P C L Transposase Stop

GCAGCTTGAGTCAGTGCGCCTTTGCGGACAAAAAATTCGGAGGTTATCCACAGTTTTTAT

, . , _{: 1} πon

CGTCGAACTCAGTCACGCGGAAACGCCTGTTTTTTAAGCCTCCAATAGGTGTCAAAAATA A A *

TCGGCACCTGCTGTATAATGCGGATTGTGGCATTTGTGCGGTGTTGCCTTAAATAAAACT

JL U O U

AGCCGTGGACGACATATTACGCCTAACACCGTAAACACGCCACAACGGAATTTATTTTGA

ATAATCAAATAGTGGGAACAAAGGATTATGATAGTCCCTTTTGTAGGGGCTTAGTTTTTT „„ , „ , „„ 11 /i π

J. _L *i KJ

TATTAGTTTATCACCCTTGTTTCCTAATACTATCAGGGAAAACATCCCCGAATCAAAAAA

GTACCCAATTTAAGAATACTTTTGCCTTATCAATTTTGACATATCCCCAAAAACAGCACT

, ~~ ——-- — 1_J.O*LΛ\JΛ\J

CATGGGTTAAATTCTTATGAAAACGGAATAGTTAAAACTGTATAGGGGTTTTTGTCGTGA CACAAACAGGTGTATGCTGTATATGTGTATGTCCGCAAATTATCATCCCCAGTGGTAAAA ₁₂60

GTGTTTGTCCACATACGACATATACACATACAGGCGTTTAATAGTAGGGGTCACCATTTT Tetracycline Start

GTATTTTACTGCTGGGGATTTTTATGCCCTTCGGGGCAGTAAAGGGAGGACAATCACATG _: __{: : :} , i oon

CATAAAATGACGACCCCTAAAAATACGGGAAGCCCCGTCATTTCCCTCCTGTTAGTGTAC

M

AAAATAATCAATATTGGAATTCTTGCCCATGTAGACGCTGGAAAGACGACCTTGACGGAG , , . , *1 OQf)

TTTTATTAGTTATAACCTTAAGAACGGGTACATCTGCGACCTTTCTGCTGGAACTGCCTC K I I N I G I L A H V D A G K T T L T E

AGCCTGCTATATGCCAGCGGAGCCATTTCAGAACCGGGGAGCGTCGAAAAAGGGACAACG ₁₄₄₀

TCGGACGATATACGGTCGCCTCGGTAAAGTCTTGGCCCCTCGCAGCTTTTTCCCTGTTGC S L L Y A S G A I S E P G S V E K G T T

AGGACGGACACCATGCTTTTGGAGCGGCAGCGTGGGATTACCATTCAAGCGGCAGTCACT __ , __: __: -i cnn

TCCTGCCTGTGGTACGAAAACCTCGCCGTCGCACCCTAATGGTAAGTTCGCCGTCAGTGA R T D T M L L E R Q R G I T I Q A A V T

TCCTTCCAGTGGCACAGATGTAAAGTCAACATTGTGGATACGCCCGGCCACATGGATTTT : 1560

AGGAAGGTCACCGTGTCTACATTTCAGTTGTAACACCTATGCGGGCCGGTGTACCTAAAA S F Q W H R C K V N I V D T P G H M D F

TTGGCGGAGGTGTACCGCTCTTTGGCTGTTTTAGATGGGGCCATCTTGGTGATCTCCGCT

_„ __, , : „: „_ __: __: : ^ C^ H

AACCGCCTCCACATGGCGAGAAACCGACAAAATCTACCCCGGTAGAACCACTAGAGGCGA L A E V Y R S L A V L D G A I L V I S A

AAAGATGGCGTGCAGGCCCAGACCCGTATTCTGTTCCATGCCCTGCGGAAAATGAACATT

— „— —■ — — — — _ _ — _IX £DΩoΠ_U

TTTCTACCGCACGTCCGGGTCTGGGCATAAGACAAGGTACGGGACGCCTTTTACTTGTAA K D G V Q A Q T R I L F H A L R K M N I

CCCACCGTTATCTTTATCAACAAGATCGACCAGGCTGGCGTTGATTTGCAGAGCGTGGTT _{: : : :} , Λ 1 A C\

GGGTGGCAATAGAAATAGTTGTTCTAGCTGGTCCGACCGCAACTAAACGTCTCGCACCAA P T V I F I N K I D Q A G V D L Q S V V nt # 1741-C substituted to T in DR10Tet-S9X CAGTCTGTTCGGGATAAGCTCTCCGCCGATATTATCATCAAGCAGACGGTGTCGCTGTCC ₁₈oo GTCAGACAAGCCCTATTCGAGAGGCGGCTATAATAGTAGTTCGTCTGCCACAGCGACAGG

Q S V R D K L S A D I I I K Q T V S L S * (amber)

CCGGAAATAGTCCTGGAGGAAAATACCGACATAGAAGCATGGGATGCGGTCATCGAAAAT ₁₈₆0

GGCCTTTATCAGGACCTCCTTTTATGGCTGTATCTTCGTACCCTACGCCAGTAGCTTTTA P E I V L E E N T D I E A W D A V I E N

AACGATAAATTATTGGAAAAGTATATCGCAGGAGAACCAATCAGCCGGGAAAAACTTGTG

10 1920

TTGCTATTTAATAACCTTTTCATATAGCGTCCTCTTGGTTAGTCGGCCCTTTTTGAACAC N D K L L E K Y I A G E P I S R E K L V

15 CGGGAGGAACAGCGGCGGGTTCAAGACGCCTCCCTGTTCCCGGTCTATTATGGCAGCGCC ₁₉₈₀

GCCCTCCTTGTCGCCGCCCAAGTTCTGCGGAGGGACAAGGGCCAGATAATACCGTCGCGG R E E Q R R V Q D A S L F P V Y Y G S A

20

AAAAAGGGCCTTGGCATTCAACCGTTGATGGATGCGGTGACAGGGCTGTTCCAACCGATT „ __: __{: i :} O C\ A f\

TTTTTCCCGGAACCGTAAGTTGGCAACTACCTACGCCACTGTCCCGACAAGGTTGGCTAA K K G L G I Q P L M D A V T G L F Q P I

25

GGGGAACAGGGGAGCGCCGCCCTATGCGGCAGCGTTTTCAAGGTGGAGTATACAGATTGC . , __: — — ,— —.— —— _— — — _ZQ.I_JL Λ_UnU

30 CCCCTTGTCCCCTCGCGGCGGGATACGCCGTCGCAAAAGTTCCACCTCATATGTCTAACG G E Q G S A A L C G S V F K V E Y T D C

GGCCAGCGGCGTGTCTATCTACGGCTATACAGCGGAACGCTGCGCCTGCGGGATACGGTG

QK „ _ _Oi en

CCGGTCGCCGCACAGATAGATGCCGATATGTCGCCTTGCGACGCGGACGCCCTATGCCAC G Q R R V Y L R L Y S G T L R L R D T V

40 GCCCTGGCCGGGAGAGAAAAGCTGAAAATCACAGAGATGCGTATTCCATCCAAAGGGGAA ___: , _: , . _: , QOOfS

CGGGACCGGCCCTCTCTTTTCGACTTTTAGTGTCTCTACGCATAAGGTAGGTTTCCCCTT A L A G R E K L K I T E M R I P S K G E

45

ATTGTTCGGACAGACACCGCTTATCCGGGTGAAATTGTTATCCTTCCCAGCGACAGCGTG „ _{: : :} , , OOQΓ_S

TAACAAGCCTGTCTGTGGCGAATAGGCCCACTTTAACAATAGGAAGGGTCGCTGTCGCAC I V R T D T A Y P G E I V I L P S D S V

50

^■ AGGTTAAACGATGTATTAGGGGACCCAACCCGGCTCCCTCGTAAAAGGTGGCGTGAGGAC 2340

TCCAATTTGCTACATAATCCCCTGGGTTGGGCCGAGGGAGCATTTTCCACCGCACTCCTG 55 R L N D V L G D P T R L P R K R W R E D CCCCTCCCCATGCTGCGGACGTCGATTGCGCCGAAAACGGCAGCGCAAΆGAGAACGGCTG

GGGGAGGGGTACGACGCCTGCAGCTAACGCGGCTTTTGCCGTCGCGTTTCTCTTGCCGAC P L P M L R T S I A P K T A A Q R E R L

CTGGACGCTCTTACGCAACTTGCGGATACTGACCCGCTTTTGCGCTGCGAGGTGGATTCC 2460

GACCTGCGAGAATGCGTTGAACGCCTATGACTGGGCGAAAACGCGACGCTCCACCTAAGG L D A L T Q L A D T D P L L R C E V D S

ATCACCCATGAGATCATTCTTTCTTTTTTGGGCCGGGTGCAGTTGGAGGTTGTTTCCGCT

TAGTGGGTACTCTAGTAAGAAAGAAAAAACCCGGCCCACGTCAACCTCCAACAAAGGCGA I T H E I I L S F L G R V Q L E V V S A

TTGCTGTCGGAAAAATACAAGCTTGAAACAGTGGTAAAGGAACCCACCGTCATTTATATG , , _{: : :} „—-. „, ZO. ORQOfUI

AACGACAGCCTTTTTATGTTCGAACTTTGTCACCATTTCCTTGGGTGGCAGTAAATATAC L L S E K Y K L E T V V K E P T V I Y M

GAGCGGCCGCTCAAAGCAGCCAGCCACACCATCCATATCGAGGTGCCGCCCAΆCCCGTTT 9£/ιn

CTCGCCGGCGAGTTTCGTCGGTCGGTGTGGTAGGTATAGCTCCACGGCGGGTTGGGCAAA E R P L K A A S H T I H I E V P P N P F

TGGGCATCCATCGGACTGTCTGTTACACCACTCCCGCTTGGCTCCGGTGTACAATACAAG 2700

ACCCGTAGGTAGCCTGACAGACAATGTGGTGAGGGCGAACCGAGGCCACATGTTATGTTC W A S I G L S V T P L P L G S G V Q Y K nt 2722-T deleted in Bbl2Tet-S139

AGCCGGGTTTCGCTGGGATACTTGAACCAGAGTTTTCAAAACGCTGTCAGGGATGGTATC OT(TfI

TCGGCCCAAAGCGACCCTATGAACTTGGTCTCAAAAGTTTTGCGACAGTCCCTACCATAG S R V S L G Y L N Q S F Q N A V R D G I G Y * (opal)

CGTTACGGGCTGGAGCAGGGCTTGTTCGGCTGGAACGTAACGGACTGTAAGATTTGCTTT 2820

GCAATGCCCGACCTCGTCCCGAACAAGCCGACCTTGCATTGCCTGACATTCTAAACGAAA R Y G L E Q G L F G W N V T D C K I C F

GAATACGGGCTTTATTACAGTCCGGTCAGCACGCCGGCGGACTTCCGCTCATTGGCCCCG 2880

CTTATGCCCGAAATAATGTCAGGCCAGTCGTGCGGCCGCCTGAAGGCGAGTAACCGGGGC E Y G L Y Y S P V S T P A D F R S L A P ATTGTATTGGAACAGGCATTGAAGGAATCAGGGACGCAACTGCTGGAACCTTATCTCTCC 2940

TAACATAACCTTGTCCGTAACTTCCTTAGTCCCTGCGTTGACGACCTTGGAATAGAGAGG I V L E Q A L K E S G T Q L L E P Y L S

TTCACCCTCTATGCGCCCCGGGAATATCTTTCCAGGGCTTATCATGATGCACCGAAATAC

AAGTGGGAGATACGCGGGGCCCTTATAGAAAGGTCCCGAATAGTACTACGTGGCTTTATG F T L Y A P R E Y L S R A Y H D A P K Y

TGTGCCACCATCGAAACGGTCCAGGTAAAAAAGGATGAAGTTGTCTTTACTGGCGAGATT

ACACGGTGGTAGCTTTGCCAGGTCCATTTTTTCCTACTTCAACAGAAATGACCGCTCTAA C A T I E T V Q V K K D E V V F T G E I

CCCGCCCGCTGTATACAGGCATACCGTACTGATCTGGCCTTTTACACCAACGGGCAGAGC , _{: :} , _, _: ___.___: _, _: ^i o π

GGGCGGGCGACATATGTCCGTATGGCATGACTAGACCGGAAAATGTGGTTGCCCGTCTCG P A R C I Q A Y R T D L A F Y T N G Q S

GTATGCCTTACAGAACTGAAAGGGTATCAGGCCGCTGTCGGCAAGCCAGTCATCCAGCCC _: , _{: :} „ on on

~ ^{1^} - "~ O _L O U CATACGGAATGTCTTGACTTTCCCATAGTCCGGCGACAGCCGTTCGGTCAGTAGGTCGGG V C L T E L K G Y Q A A V G K P V I Q P

Tetracycline Stop

CGCCGTCCAAACAGCCGCCTGGACAAGGTGCGCCATATGTTCAGTAAGATCACTTGATAC _ _ •ao_/m

GCGGCAGGTTTGTCGGCGGACCTGTTCCACGCGGTATACAAGTCATTCTAGTGAACTATG R R P N S R L D K V R H M F S K I T *

Nucleotide sequence of the inactive TetW transposon from Bifidobacterium animalis subsp. Lactis Bb-12®.The sequence was obtained by sequencing at Chr. Hansen A/S. Upstream is the transposase encoding open reading frame, nt. # 4 -966, with the amino acid depicted under the DNA sequence (M. W. approx.35 kDa). The nt. sequence # 1318-3234 is the tetracycline resistant encoding gene, tetW, with the amino acid outlined under the DNA sequence. (M. W. approx.70 kDa).

The amber mutation at nt position # 1741 (nt # 424 relative to the start codon of tetW) for the tetracycline sensitive strain, DR10Tet-S9X (CHCC9070), is indicated above the DNA sequence. The frameshift mutation at nt position # 2722 (nt #1405 relative to the start codon) for the tetracycline sensitive strain, Bb12Tet-S139 (CHCC8902), is indicated above the DNA sequence. *): indicates a stop codon.

Claims

1. A method of inactivating a tetWgene in a Bifidobacterium sp. (Bifidobacteriaceae) cell, said method comprising subjecting a Bifidobacterium sp. cell comprising a func- tional tetWgene to a chemical mutagen and a physical mutagen.

2. A method of preparing a Bifidobacterium sp. cell comprising an inactivated teM/gene, said method comprising the steps of: a) inactivating a tetW gene in a Bifidobacterium sp. cell comprising a functional tefl/l/ gene according to claim 1 b) isolating a mutant of the Bifidobacterium sp. cell obtained from step a) which has an inactivated tetWgene.

3. The method according to claim 2, wherein the Bifidobacterium sp. cell comprising a functional tetWgene has a Minimum Inhibitive Concentration of 4 microgram tetracy- cline/ml or higher.

4. The method according to any of claims 2-3, wherein the mutant Bifidobacterium sp. cell comprising an inactivated tetWgene has a Minimum Inhibitive Concentration of 1.5 microgram tetracycline/ml or less.

5. The method according to any of the preceding claims, wherein the functional tetW gene is located on the chromosome of the Bifidobacterium sp. cell.

6. A method of preparing a tetracycline sensitive Bifidobacterium sp. cell, said method comprising the steps of: a) subjecting a Bifidobacterium sp. cell to a chemical mutagen and a physical mutagen, wherein the Bifidobacterium sp. cell has a Minimum Inhibitive Concentration of 4 microgram tetracycline/ml or higher b) isolating a mutant of the Bifidobacterium sp. cell obtained from step a), wherein said mutant has a Minimum Inhibitive Concentration of 1.5 microgram tetracycline/ml or less.

7. The method according to any of claims 2-6, wherein the chemical mutagen is an intercalating UV-absorbing chemical and the physical mutagen is a non-ionizing radiation with a wavelength shorter than 800 nm.

8. The method according to claim 7, wherein the intercalating UV-absorbing chemical is selected from the group consisting of ethidium bromide (EtBr), ethidium, proflavine, daunomycin, adriamycin, actinomycin, ellipticine, tilorone, m-AMSA, mithramycin, ne- tropsin, irehdiamine A, anthramycin, steptonigrin, bleomycin, ditercalinium, triostin, and echinomycin.

9. The method according to any of claims 3-8, wherein the Minimum Inhibitive Concentration is determined by: a) dipping a sterile cotton swab into a culture, which has grown overnight, of a tetracycline sensitive strain to be tested, b) streaking the entire surface of a MRS agar plate (diameter: 8,5 cm) evenly in three directions with the cotton swab from step a) c) when the inoculum applied in step b) has dried, applying an E-test strip to the agar surface by help of a manual applicator with the MIC scale facing upwards d) inoculating the agar plate anaerobically in an inverted position at 37 ⁰C overnight e) determining the MIC value by reading the value where the edge of the inhibition ellipse intersects the strip.

10. The method according to any of the preceding claims, wherein the Bifidobacterium sp. cell which comprises a functional tetW gene or has a Minimum Inhibitive Concen- tration of 4 microgram tetracycline/ml or higher is selected from the group of strains consisting of Bifidobacterium animalis subspecies lactis strain CHCC5445 (Bb-12®), deposited on September 30 , 2003 with the Deutsche Sammlung von Mikroorganis- men und Zellkulturen under accession number DSM15954, and, Bifidobacterium animalis subspecies lactis strain CHCC7158, deposited on April 28, 2005 with the Deutsche Sammlung von Mikroorganismen und Zellkulturen under accession number DSM17280.

11. The method according to any of claims 2-10, wherein step b) comprises the steps of: i) determining the minimum inhibitive concentration (MIC) of the bacteria by the Etest susceptibility screening method, ii) dividing the bacteria into two classes based on the result of the Etest susceptibility screening: Class 1 : bacteria with a MIC of 1.5 μg/ml or less according to the Etest, and

Class 2: bacteria with a MIC over 1.5 μg/ml according to the Etest; and iii) identifying and expanding those antibiotica sensitive bacteria identified in ii) with a MlC of 1.5 μg/ml or less (Class 1).

12. The method according to claim 11 , wherein tetracyclines is tetracycline.

13. The method according to any of the preceding claims, wherein the Bifidobacterium sp. cell comprising a functional tetW gene or that has a Minimum Inhibitive Concen- tration of 4 microgram tetracycline/ml or higher is a probiotic cell.

14. The method according to any of the preceding claims, wherein the mutant Bifidobacterium sp. cell comprising an inactivated tetW gene or has a Minimum Inhibitive Concentration of 1.5 microgram tetracycline/ml or less is a probiotic cell.

15. The method according to any of the preceding claims, wherein the method comprises the steps of: i) culturing the Bifidobacterium sp. cell comprising a functional tetW gene or that has a Minimum Inhibitive Concentration of 4 microgram of tetracycline/ml or higher to obtain a culture of exponential growing cells, ii) transferring an aliquot of the cells obtained in step i) to fresh medium containing ethidium bromide (EtBr), iii) transferring the culture obtained in step ii) to one or more containers to form a 0.5 - 10 mm thick layer of culture, iv) subjecting the culture(s) of step iii) to a UV treatment, v) culturing the mutated cells obtained from step iv) to obtain a culture of exponential growing cells, vi) transferring an aliquot of bacteria to one or more petridishes containing a suitable agar growh medium, the aliquot of bacteria are selected to give single colonies, vii) identifying those colonies from step vi) that have acquired antibiotic 5 sensitivity by replica plating to petridishes with and without antibiotic, and viii) isolating and expanding the cell obtained in step vii).

16. The method according to claim 15, wherein the culture obtained in step iv) is sub- 10 jected to an enrichment step for mutations comprising the steps of: iva) transferring an aliquot of the UV treated culture to fresh medium containing a dose of a penicillin analogue which is detrimental to exponentially growing cells, but tolerable to non-growing cells, and ivb) culturing the cells in said penicillin analogue comprising medium under condi- 15 tions, which would promote exponential growth in the absence of penicillin or an analogue of penicillin such as ampicillin.

17. The method according to any of the previous claims, wherein the culture is performed at a reduced oxygen tension.

20

18. The method according to claim 16, wherein the UV-treatment of step iv) reduces the number of living cells measured by Colony Forming Units (CFUs) to less that 20% relative to the number of the CFUs of the culture immediately before the UV-treatment.

25 19. The method according to claim 16, wherein the penicillin analogue is amphicillin being used at a dose of 50-300 ug/ml medium.

20. The method according to any of the preceeding claims, wherein tetracyclines is a antibioticum selected from the group of tetracycline, terramycin, demeclocycline, meclo-

30 cycline, doxycycline / doxycyclin, lymecycline, methacycline, minocycline, oxytetracy- cline, rolitetracycline, aureomycin and other chlortetracyclines.

21. The method according to any of the preceeding claims, wherein the Bifidobacterium sp. cell comprising a functional tetW gene or that has a Minimum Inhibitive Concentra-

35 tion of 4 microgram tetracycline/ml or higher is selected from the group consisting of Bi- fidobacteriacea comprising Bifidobacterium longum, Bifidobacte-rium pseudocatenula- tum, Bifidobacterium bifidum, Bifidobacterium lactis, Bifidobacterium animalis and subspecies thereof.

5 22. The method according to any of the preceeding claims, wherein the Bifidobacterium sp. cell comprising a functional tetW gene or has a Minimum Inhibitive Concentration of 4 microgram of tetracycline/ml or higher is a strain of Bifidobacterium animalis subspecies lactis.

10 23. The method according to any of the preceeding claims, wherein the Minimum inhibitive Concentration (MIC) of antibiotic of the Bifidobacterium sp. cell comprising a functional tetW gene or the Bifidobacterium sp. cell that has a Minimum Inhibitive Concentration of 4 microgram tetracycline/ml or higher, is at least 10-fold higher than the MIC of the mutant Bifidobacterium sp. cell comprising an inactivated tefWor the mutant Bifido-

15 bacterium sp. cell that has a Minimum Inhibitive Concentration of 1.5 microgram tetracycline/ml or less .

24. The method according to any of the preceeding claims, wherein the Minimum inhibitive Concentration (MIC) of tetracycline of the Bifidobacterium sp. cell comprising a func-

20 tional tetW gene or the Bifidobacterium sp. cell that has a Minimum Inhibitive Concentration of 4 microgram tetracycline/ml or higher, is at least 10 microgram/ml and the MIC of tetracycline of the mutant Bifidobacterium sp. cell comprising an inactivated tetWor tne mutant Bifidobacterium sp. cell that has a Minimum Inhibitive Concentration of 1.5 microgram tetracycline/ml or less, is 1 microgram/ml or less.

25

25. A Bifidobacterium sp. cell comprising an inactivated tetW gene.

26. The Bifidobacterium sp. cell according to claim 25, wherein said strain has a Minimum Inhibitive Concentration of 1.5 microgram tetracycline /ml or less.

30

27. The Bifidobacterium sp. cell according to any of claims 25-26, wherein the inactivated tet W gene is located on the chromosome of said cells.

28. A Bifidobacterium sp. cell which has a Minimum Inhibitive Concentration of 1.5 mi- 35 crogram tetracycline/ml or less.

29. A Bifidobacterium sp. cell containing a mutated, chromosomally encoded tetW rendering the cell sensitive to tetracyclines obtainable by the method of of any of claims 2- 24.

30. The Bifidobacterium sp. cell according to any of claims 25-29, wherein the cell is selected from the group consisting of Bifidobacteriacea comprising Bifidobacterium Iongum, Bifidobacterium pseudocatenulatum, Bifidobacterium bifidum, Bifidobacterium lactis, Bifidobacterium animalis and subspecies thereof.

31. The Bifidobacterium sp. cell according to claim 30, wherein the cell is of the strain of Bifidobacterium animalis subspecies lactis.

32. A Bifidobacterium cell which is sensitive to tetracyclines due to a mutation in tetW, said Bifidobacterium cell being derived from a progenitor cell which is resistant to tetracyclines due to the presence of a tet W gene located on the chromosome.

33. The Bifidobacterium cell according to any of claims 26-32, wherein tetracyclines is an antibiotic selected from the group consisting of tetracycline, terramycin, demeclo- cycline, meclocycline, doxycycline/doxycyclin, lymecycline, methacycline, minocycline, oxytetracycline, rolitetracycline, aureomycin and other chlortetracyclines.

34. The Bifidobacterium cell according to any of claims 32 or 33, wherein the progenitor cell is selected from the group consisting of Bifidobacteriacea comprising Bifidobacte- rium Iongum, Bifidobacterium pseudocatenulatum, Bifidobacterium bifidum, Bifidobacterium lactis, Bifidobacterium animalis and subspecies thereof.

35. The Bifidobacterium cell according to claim 34, wherein the progenitor cell is of the strain of Bifidobacterium animalis subspecies lactis.

36. The Bifidobacterium cell according to claim 35, wherein the progenitor cell is of the strain of Bifidobacterium animalis subspecies lactis strain CHCC5445 (Bb-12®), deposited on September 30 , 2003 with the Deutsche Sammlung von Mikroorganismen und Zellkulturen under accession number DSM15954.

37. The Bifidobacterium cell according to claim 35, wherein the progenitor cell is of the strain of Bifidobacterium animalis subspecies lactis strain CHCC7158, deposited on April 28, 2005 with the Deutsche Sammlung von Mikroorganismen und Zellkulturen under accession number DSM17280.

5

38. The Bifidobacterium cell according to any of claims 32 to 37, wherein the Minimum inhibitive Concentration of antibiotic (MIC) of the progenitor cell is at least 10-fold higher than the MIC of the antibiotic sensitivecell.

10 39. The Bifidobacterium cell according to any of claims 32 to 37, wherein the Minimum inhibitive Concentration (MIC) of tetracycline of the progenitor cell is at least 10 microgram tetracycline/ml and the MIC of the antibiotic sensitive cell is 1.5 microgram tetracy- cline/ml or less.

15 40. The Bifidobacterium cell according to any of claims 25 to 39 or claims 71 to 73, wherein the inactivated or mutated tetWgene comprises at least one sequence selected from the group of SEQ ID 3 [GGATACTGAACC], SEQ ID NO: 6 [GTGGTTTAGTCT], SEQ ID 25 [ATACTGAA], SEQ ID NO: 27 [ACCAGCGT TTTC], SEQ ID 28 [CGCCCTGCCACA], SEQ ID 29 [ATATTGTCATCA], SEQ ID 30 [TAGACGATGGAA],

20 SEQ ID 31 [CGGTCCGGGTAA], SEQ ID 32 [CTGATCCGGCCTT], [CAGCGTTT]₁ [GACGATGG], [GTCCGGGT], [ATCCGGCC], [CCTGCCAC], [TTGTCATC], [GGTTTAGT], [GTGGACCG], [CGCCCATT], and [TCCGGCCC].

41. The Bifidobacterium cell according any of claims 25 to 39 or claims 71 to 73,

25 wherein the inactivated or mutated tetWgene comprises the sequences [CCTGCCAC] and [TTGTCATC].

42. The Bifidobacterium cell according any of claims 25 to 41 or claims 71 to 73, wherein the inactivated or mutated teflV gene comprises the sequences SEQ ID NO: 28

30 [CGCCCTGCCACA] and SEQ ID NO: 29 [ATATTGTCATCA].

43. The Bifidobacterium cell according any of claims 25 to 37 or claims 71 to 73, wherein the inactivated or mutated tetWgene comprises the sequences [GACGATGG], [GTCCGGGT] and [ATCCGGCC].

35

44. The Bifidobacterium cell according any of claims 25 to 41 or claims 71 to 73, wherein the inactivated or mutated tetWgene comprises the sequences SEQ ID NO: 30 [TAGACGATGGAA], SEQ ID NO: 31 [CGGTCCGGGTAA] and SEQ ID NO: 32

5 [CTGATCCGGCCTT].

45. The Bifidobacterium cell according to claim 40, wherein the inactivated or mutated tetW gene comprises SEQ ID NO: 3 [GGATACTGAACC].

10 46. The Bifidobacterium cell according to claim 40, wherein the inactivated or mutated tetWgene comprises SEQ ID NO: 6 [GTGGTTTAGTCT].

47. The Bifidobacterium cell according to claim 40, wherein the inactivated or mutated tetWgene comprises SEQ ID NO: 27 [ACCAGCGTTTC].

15

48. The Bifidobacterium cell according to any of claims 25 to 43 or claims 71 to 73, which is identified as Bifidobacterium animalis subspecies lactis strain CHCC8902 (Bb- 12Tet-S139) and deposited on April 28, 2005 with the Deutsche Sammlung von Mikro- organismen und Zellkulturen under accession number DSM17281.

20

49. The Bifidobacterium cell according to any of claims 25 to 42, claim 43 or claims 71 to 73, which is identified as Bifidobacterium animalis subspecies lactis strain CHCC9070 (DR10Tet-S9X) and deposited on April 28, 2005 with the Deutsche Sammlung von Mik- roorganismen und Zellkulturen under accession number DSM17282.

25

50. Use of a Bifidobacterium cell according to any of claims 25 to 49 for the preparation of an ingestible material or a bacterial culture.

51. The use according to claim 50, wherein the bacterial culture is further processed. 30

52. The use according to claim 50, wherein the ingestible material is a fermentated food or feed product.

53. The use according to claim 52, wherein the fermentated food or feed product is fur- 35 ther processed.

54. The use according to claim 50, wherein the ingestible material comprises Bifidobacteria in an amount from about 10⁵ cfu/g to about 10¹² cfu/g ingestible material.

55. The use according to any of the claims 50 to 54, wherein the ingestible material is a composition selected from the group consisting of milk, curd, milk based fermented products, acidified milk, yoghurt, frozen yoghurt, milk powder, milk based powders, milk concentrate, cheese, cheese spreads, dressings, beverages, ice creams, fermented cereal based products, infant formulae, and soybean milk.

56. The use according to any of the claims 50 to 55, wherein the ingestible material is used for the preparation of a composition for the treatment and/or prevention of a disease, syndrome or condition, or for improving digestion of nutrients, or for improving the general health status of a human being or a vertebrate animal.

57. The use according to any of the claims 50 to 56, wherein the ingestible material is used as a probiotic.

58. The use according to claims 50 or 57, wherein the ingestible material is a composi- tion selected from the group consisting of milk, curd, milk based fermented products, acidified milk, yoghurt, frozen yoghurt, milk powder, milk based powders, milk concentrate, cheese, cheese spreads, dressings, beverages, ice creams, fermented cereal based products, infant formulae, tablets, capsules, liquid bacterial suspensions, dried oral supplement, wet oral supplement, dry tube feeding, or wet tube feeding.

59. The use according to claim 56, wherein said disease, syndrome or condition is selected from the group consisting of antibiotic-associated disorders, gastroenteritis, diarrhoea including traveller's diarrhoea and acute infantile diarrhoea, lactose intolerance, gastrointestinal infections and colonization of the gastrointestinal tract by pathogenic bacteria including Helicobacter pylori and Clostridium difficile, irritable bowel syndrome (IBS), inflammatory bowel disease (IBD), colonic cancer, urogenital infections and tumours, vaginal infections, allergy (especially atopic eczema), vaccination, cho- lestrolemia, and hypertension.

60. The use according to any of claims 56 to 59, wherein the ingestible material is suitable for preventing or treating infections with pathogens.

61. A food or feed product comprising the bacterial cell of any of claims 25 to 49. 5

62. The use of a Bifidobacterium cell according to any of claims 25 to 49 for the preparation of a starter culture.

63. Use according to claim 62, wherein the starter culture is frozen. 10

64. Use according to claim 62, wherein the starter culture is freeze dried.

65. Use according to claim 62, wherein the starter culture is spray dried or fluid bed dried.

15

66. A starter culture composition comprising the bacterium of any of claims 25 to 49, preferably wherein the starter culture composition has a concentration of viable cells, which is in the range of 10⁴ to 10¹² cfu per gram of the composition.

20 67. The starter culture composition according to claim 66, which in addition comprises one or more cryoprotective agent(s) selected from the group consisting of inosine-5'- monophosphate (IMP), adenosine-5'-monophosphate (AMP), guanosine-5'- monophosphate (GMP), uranosine-5'-monophosphate (UMP), cytidine-5'- monophosphate (CMP), adenine, guanine, uracil, cytosine, adenosine, guanosine,

25 uridine, cytidine, hypoxanthine, xanthine, hypoxanthine, orotidine, thymidine, inosine and a derivative of any of such compounds.

68. A method for making a frozen starter culture comprising the following steps:

1. culturing a bacterial cell according to claims 25 to 49 30 2. harvesting the propagated cells to provide a concentrated bacterial culture,

3. freezing the bacterial material to get frozen material, and

4. packing the freeze dried material in a suitable container.

69. A method for making a freeze dried starter culture comprising the following steps: 35 1. culturing a bacterial cell according to claims 25 to 49

2. harvesting the propagated cells to provide a concentrated bacterial culture,

3. freezing the bacterial material to get frozen material,

4. sublimation of water from the frozen material, and

5. packing the freeze dried material in a suitable container. 5

70. A method according to claims 68 or 69, wherein step 3 is performed by dripping the concentrated culture into liquid nitrogen and collecting the frozen material.

71. The Bifidobacterium cell according to any of claims 25 to 39, wherein the mutated or 10 inactivated tetW gene comprises at least one sequence selected from the group of

[ATACTGAA], [GGTTTAGT] and [CAGCGTTT].

72. The Bifidobacterium cell according any of claims 25 to 39, wherein the mutated or inactivated tetW gene comprises the sequences [CCCTGCCA] and [ATTGTCAT].

15

73. The Bifidobacterium cell according to any of claims 25 to 39, wherein the mutated or inactivated tetW gene comprises the sequences [GACGATGG], [GTCCGGGT] and [GATCCGGC].

20 74. A Bifidobacterium sp.cell according to any of claims 25-49 for the use as a probiotic.

75. A method of treating a mammal comprising administering a Bifidobacterium sp.cell according to any of claims 25-49.

25 76. The method according to any of claims 2-24, wherein said method after step a) further comprises the steps of: i) transferring an aliquot of the UV treated culture to fresh medium containing a dose of a penicillin analogue which is detrimental to exponentially growing cells, but tolerable to non-growing cells, and

30 ii) culturing the cells in said penicillin analogue comprising medium under conditions, which would promote exponential growth in the absence of penicillin or an analogue of penicillin such as ampicillin.